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Abstract
During	mammalian	neural	development, a	wide	variety	of	neurons	and	glial	cells
differentiate	 from	 common	 neural	 progenitor	 cells	 (NPCs). Postnatally, some	 of
these	cells	transform	to	adult	neural	stem/progenitor	cells	which	reside	in	specialized
niches	where	they	continue	to	produce	neurons. The	mechanisms	controlling	NPC
fate, however, are	not	fully	understood. Microarray	analysis	of	ribosome-enriched
transcripts	in	NPCs	revealed	a	preferential	loading	of	ribosomes	with	transcripts	im-
portant	for	neuronal	differentiation. One	preferentially	loaded	transcript	is	Ankyrin
repeat	 and	KH domain-containing	protein 1	 (ANKHD1). ANKHD1	 is	 a	270 kDa
protein	that	has	been	shown	to	play	important	roles	in	progenitor	cell	proliferation,
differentiation, and	survival. Moreover, it	was	found	to	be	deregulated	in	several
cancers, including	some	leukemias. Due	to	its	apparent	role	in	progenitor	cell	regu-
lation, ANKHD1	may	also	be	an	important	functional	regulator	in	NPCs. However,
no	function	for	ANKHD1	in	the	mammalian	brain	has	been	described	so	far.
The	present	project	aims	at	elucidating	the	role	of	ANKHD1	in	embryonic	and	adult
neural	progenitor	cells	in	mice. We	show	that	ANKHD1	is	expressed	throughout
murine	embryonic	brain	development	and	in	adult	neural	progenitor	cells. Expres-
sion	can	be	detected	as	early	as	E12.5	and	is	robust	during	the	course	of	cortical
development. Selective	 knockdown	 of	ANKHD1	 via in	 utero electroporation	 in
the	developing	neocortex	promotes	apical	and	basal	progenitor	proliferation	and
inhibits	differentiation	into	neurons. This	phenotype	could	be	rescued	by	simulta-
neous	overexpression	of	human	ANKHD1. Similar	to	NPCs	during	development,
knockdown	of	ANKHD1	in	primary	neurosphere	cultures	of	adult	NPCs	promotes
their	proliferation	and	inhibits	neuronal	differentiation. Deregulation	of	embryonic
and	adult	neural	progenitor	cells	can	lead	to	the	development	of	brain	cancers, such
as	glioblastoma	multiforme. Accordingly, deregulation	of	ANKHD1	in	glioma	initi-
ating	cells	inﬂuences	their	proliferative	capacity. Together, these	results	substantiate
the	relevance	of	ANKHD1	for	controlling	proliferation	and	differentiation	of	neural
progenitors.
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Zusammenfassung
Während	der	Entwicklung	des	Nervensystems	von	Säugetieren	differenzieren	eine
Vielzahl	von	Neuronen	und	Gliazellen	aus	gemeinsamen	neuralen	Vorläuferzellen
(NPCs). Einige	NPCs	werden	postnatal	 zu	 adulten	neuralen	 Stamm-	 /	Vorläufer-
zellen, die	sich	in	spezialisierten	Nischen	beﬁnden	und	weiterhin	Neuronen	pro-
duzieren. Die	Mechanismen, die	das	NPC Schicksal	kontrollieren	sind	nicht	voll-
ständig	verstanden. Microarray	Analysen	von	Ribosom-angereicherten	Transkripten
in	NPCs	haben	gezeigt, dass	Ribosomen	bevorzugt	mit	Transkripten	geladen	wer-
den, die	wichtig	für	neuronale	Differenzierung	sind. Ankyrin	repeat	and	KH domain-
containing	protein 1	(ANKHD1)	ist	eines	dieser	vorrangig	geladenen	Transkripte. Es
spielt	wichtige	Rollen	in	der	Regulation	von	Proliferation, Differenzierung	und	dem
Überleben	von	Vorläuferzellen	und	kann	in	mehreren	Krebsarten	dereguliert	sein.
Aufgrund	der	Rolle	von	ANKHD1	bei	der	Regulierung	von	Vorläuferzellen, könnte
es	auch	ein	wichtiger	Regulator	von	NPCs	sein. Allerdings	 ist	bisher	noch	keine
Funktion	von	ANKHD1	im	Säugerhirn	beschrieben.
Das	vorliegende	Projekt	untersucht	die	Rolle	von	ANKHD1	 in	embryonalen	und
adulten	neuralen	Vorläuferzellen. Wir	zeigen, dass	ANKHD1	während	der	gesamten
murinen	embryonalen	Entwicklung	des	Gehirns, als	auch	in	adulten	neuralen	Vor-
läuferzellen	exprimiert	wird. Die	Expression	kann	bereits	am	Tag	E12.5	nachge-
wiesen	werden	und	bleibt	im	Verlauf	der	kortikalen	Entwicklung	robust. Selektiver
Knockdown	von	ANKHD1	durch in	utero Elektroporation	im	sich	entwickelden	Neo-
cortex	fördert	die	Proliferation	von	apikalen	und	basalen	Vorläuferzellen	und	hemmt
ihre	Differenzierung	in	Neuronen. Dieser	Phänotyp	kann	durch	die	gleichzeitige
Überexpression	von	humanem	ANKHD1	gerettet	werden. Ähnlich	wie	 in	NPCs
während	der	Entwicklung, führt	ein	knockdown	von	ANKHD1	in	Primärkulturen	von
adulten, als	Neurosphären	wachsenden	NPCs	zu	stärkerer	Proliferation	und	hemmt
die	neuronale	Differenzierung. Deregulierung	von	embryonalen	und	adulten	NPCs
kann	zur	Entstehung	von	Gehirntumoren, wie	z.B.	Glioblastoma	Multiforme, führen.
Wir	konnten	zeigen, dass	eine	Deregulierung	von	ANKHD1	in	Glioma	initiierenden
Zellen	ihre	Proliferation	beeinﬂusst. Zusammengenommen	belegen	unsere	Ergeb-
nisse	die	Bedeutung	von	ANKHD1	für	die	Steuerung	der	Proliferation	und	Differen-
zierung	von	neuralen	Vorläuferzellen.
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1 Introduction
1.1 Function	of	stem	and	progenitor	cells	during	development	and	adulthood
Multicellular	organisms	develop	from	pluripotent	stem	cells	that	are	capable	of	gen-
erating	all	cell	types	of	the	organism. Often, more	restricted	pluri-	and	uni-potent
stem	cells	remain	after	development	to	maintain	tissues	throughout	life. The	regula-
tion	of	stem	/	progenitor	cell	activity	is	the	basis	of	sustainable	life	for	many	organ-
isms, including	mammals. During	development, regulation	of	progenitor	identity,
symmetric	and	asymmetric	divisions, and	differentiation	properties	 is	essential	 to
generate	–	at	 the	right	time	and	at	 the	appropriate	place	–	the	correct	amount	of
differentiated	cells.
In	adult	organisms, some	tissues	need	constant	progenitor	activity	to	maintain	their
integrity	and	function. Examples	for	such	are	the	blood	system	and	intestine, were
mature	cells	have	short	average	life	spans. Without	constant	generation	of	newly
differentiated	cells, these	tissues	would	degenerate	and	stop	providing	essential	life
functions. Other	tissues	contain	few	or	no	stem	/	progenitor	cells, and	these	are	often
found	to	be	restricted	to	certain	regions	in	the	organ. In	many	of	these	previously
referred	to	as	”quiescent	tissues”, stem	/	progenitor	cells	were	discovered	during	the
last	two	decades	and	shown	to	be	functionally	relevant. One	example	of	such	a
tissue	is	the	mammalian	brain, were	most	of	the	cells	are	post	mitotic	and	remain
functional	throughout	life. However, stem	cell	niches	and	regions	where	new	cells
are	added	to	the	system	or	replace	other	cells	have	been	identiﬁed	in	recent	years
(see	section 1.4.1). Moreover, in	some	tissues, progenitor	cells	can	react	to	certain
stimuli	(such	as	injury)	and	accordingly	change	their	proliferation	and	differentiation
programs. For	instance, bronchioalveolar	stem	cells	in	the	lung	proliferate	during
epithelial	cell	 renewal	 [46], and	progenitors	 in	 the	brain	can	be	activated	–	and
change	the	fate	of	their	progenies	–	following	insults	such	as	stroke	or	ischemia	(see
Nakafuku M [61] for	reviews). However, also	non-injury	/	 tissue	damage	related
changes	do	occur	in	progenitor	cells. For	instance, increase	of	neuronal	output	after
physical	activity	(running	[96]	and	learning	[32])	has	been	reported. Besides	their
tissue	repair, maintenance, and	other	physiological	functions, stem	/	progenitor	cells
have	been	also	connected	to	disease	development, e.g. in	cancer	(see 1.4.2).
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In	 line	with	 the	scope	of	 the	presented	thesis, the	 following	sections	will	discuss
mammalian	brain	development	in	more	detail, followed	by	short	introductions	of
adult	neurogenesis	and	the	relation	of	neural	progenitor	cells	(NPCs)	to	cancers	in
the	brain.
1.2 Mammalian	brain	development
The	mammalian	brain	is	a	remarkable	organ, endowed	with	enormous	processing
power	and	fascinating	capabilities. An	average	human	brain	consists	of	approxi-
mately	86	billion	neurons	of	many	thousand	different	types	[6], which	form	approx-
imately	100-500	trillion	synaptic	connections	between	them	[21]. The	other	major
cell	type	found	in	the	brain	are	glial	cells	(astrocytes	and	oligodendrocytes)	which
are	similarly	abundant	as	neurons	in	humans1. Other	cell	types	residing	in	the	brain
include	ependymal	cells, choroid	plexus	cells	(which	are	modiﬁed	ependymal	cells
that	generate	the	cerebral	spinal	ﬂuid), and	microglia	(”macrophages	of	the	brain”).
Moreover, immune	cells	can	inﬁltrate	 the	brain	after	 injury	and	other	stimuli	 (re-
viewed	in	Rezai-Zadeh	et al. [69]).
In	the	following	sections, mammalian	brain	development	will	be	explained	based
on	the	mouse	as	a	model	organism. While	many	steps	in	mouse	and	human	brain
development	are	very	similar	and	many	basic	mechanisms	seem	to	be	identical, it	is
obvious	that	some	differences	must	be	present	to	explain	features	of	the	brain	unique
to	humans. Some	of	these	have	been	described	and	studied	while	others	are	still
poorly	understood. For	instance, the	differences	in	the	ratio	of	neurons	to	glial	cells
have	been	described	[6], and	the	evolvement	of	a	gyrencephalic	brain	in	humans
(i.e. their	cortical	 layers	 form	 folded	structures	as	consequence	of	a	 tremendous
expansion	of	 cell	numbers)	 versus	 the	 lissencephalic	brain	of	mice	are	currently
studied. Nonetheless, many	mechanisms	studied	and	discovered	in	mice	hold	true
for	human	brain	development	 and	are	used	as	 foundation	 to	understand	human
brain	function	and	development	of	disease	treatment.
Development	of	the	brain	begins	around	gestational	day	7.5	to	9.5	(E 7.5	to	E 9.5)
in	mice	(gestational	week	(GW) three	in	humans)	with	the	emergence	of	the	neural
plate, and	is	a	protracted	process	not	completed	until	late	adolescents	[86]. First,
1Mice	and	other	rodents	have	more	neurons	then	glia
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neuroepithelial	cells	are	generated	from	the	ectoderm	to	form	the	neural	plate	and
followed	by	the	neural	 tube. The	most	anterior	part	of	 the	neural	 tube	forms	the
brain, while	 the	 remaining	 neural	 tube	 develops	 into	 the	 spinal	 column. Three
vesicle-like	structures, the	prosencephalon, mesencephalon, and	rhombencephalon
arise	from	the	most	anterior	part	of	the	neural	tube	at	E10.5	in	mice	and	E28	in	hu-
mans, representing	 the	basic	structures	 from	which	the	brain	develops	[86]. The
prosencephalon, the	embryonic	precursor	of	 the	 forebrain, will	 further	subdivide
into	the	telencephalon	and	diencephalon. The	rhombencephalon	subdivides	into
the	metencephalon	and	myelencephalon, while	the	mesencephalon	does	not	further
subdivide. These	ﬁve	vesicles, aligned	along	the	rostral-caudal	axis	of	the	embryo
represent	the	primary	organization	of	the	central	nervous	system	(CNS) [85].
1.3 Neural	development	in	the	mammalian	forebrain
As	mentioned	above, the	forebrain	develops	from	the	telencephalon	and	dience-
phalon. From	the	diencephalon	the	more	posterior	forebrain	structures	are	formed,
including	the	thalamus, subthalamus, hypothalamus	and	epithalamus	[42]. The	te-
lencephalon	on	the	other	hand	develops	into	the	cerebrum, which	consists	of	the
cerebral	cortex, hippocampus, basal	ganglia, and	olfactory	bulbs. Basal	ganglia
mainly	 consist	 of	 (amongst	other	 groups	of	nuclei)	 the	 striatum, globus	pallidus,
substantia	nigra, nucleus	accumbens, and	subthalamic	nucleus.
Within	 the	cerebrum, the	cerebral	 cortex	 forms	 the	neocortex, archicortex	 (Hip-
pocampus)	and	paleocortex. The	neocortex	accounts	for	approximately	three	quar-
ters	of	human	brain	volume	and	is	responsible	for	higher	functions, such	as	con-
scious	thought, language, and	sensory	perception. Evolutionary, it	is	the	newest	part
of	the	cerebral	cortex. It	is	built	up	of	a	six	layered	structure	that	is	lissencephalic
(i.e. ”smooth”)	in	mice, rats, and	many	other	rodents, but	is	folded	(i.e. has	sulci
and	gyri)	in	primates	and	some	other	mammals, due	to	the	massive	expansion	of
neural	precursor	cells	in	these	animals. The	neocortex	is	apparently	a	distinguish-
ing	feature	of	mammals, responsible	for	the	highest	neural	functions, and	is	the	most
studied	structure	of	the	brain. The	work	with	embryonic	neural	progenitors	(eNPCs)
in	this	thesis	is	focused	on	the	developing	neocortex.
The	structural	foundations	of	the	developing	telencephalon	are	established	by	early
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patterning	events. Diffusible	morphogens, released	from	signaling	centers	in	and
around	the	telencephalon	instruct	the	antero-posterior	and	later	dorso-ventral	pat-
terning	of	 the	 telencephalon. The	main	 signaling	centers	are	 the	anterior	neural
ridge	(later	commisural	plate; ANR/CoP),	the	cortical	hem, the	anti-hem	(or	pallial-
subpallial	boundary	(PSB)) and	the	ventral	signaling	center	(see	Fig. 1 for	an	illus-
tration	of	signaling	centers	and	patterning). The	main	signaling	molecules	include
various	FGF ligands, BMPs	/	Wnt, and	Sonic	Hedgehog	(SHH).	For	instance, FGF8
is	produced	rostrally	in	the	ANR/CoP,	while	BMPs	and	Wnt	are	expressed	caudally
and	dorsally	in	the	cortical	hem. FGF7	and	TGF-a	are	produced	in	the	anti-hem	and
SHH expression	deﬁnes	the	ventral	signaling	center	(see	Götz	and	Sommer [35] and
Iwata	and	Hevner [41] for	reviews).
Expression	of	these	signaling	molecules	in	deﬁned	areas	establishes	unique	gradient
patterns. According	to	these	gradients, expression	of	transcription	factors	in	neu-
roepithelial	cells, such	as	Pax6, Emx2, Coup-Tf1, and	Sp8	is	induced	and	regulated
(Figure 1 B).	The	combinations	of	these	transcription	factor	gradients	ultimately	lead
to	formation	of	the	prospective	area	boundaries	[41].
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Figure 1: Patterning in the telencephalon. Modiﬁed from Iwata and Hevner [41]. Signaling centers
(A) establish transcription factor (TF) gradients (B) which form prospective area boundaries. ANR/CoP
= anterior neural ridge / commisural plate; Shh = Sonic Hedgehog; A = anterior; P = posterior; D =
dorsal; V = ventral.
1.3.1 Neocortical	development
At	the	onset	of	neocortical	development, around	E9-10	in	the	mouse	[48], the	entire
ventricular	zone	(VZ) is	a	pseudostratiﬁed	epithelium	consisting	exclusively	of	neu-
roepithelial	cells	[14]. These	cells	divide	rapidly	and	symmetrically	to	expand	their
population	pool, before	their	gradual	transition	into	radial	glia	(RG) cells. RG cells
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have	their	cell	body	located	in	the	VZ,	are	in	contact	with	the	apical	surface	of	the
developing	neocortex, and	extend	a	radial	ﬁber	that	reaches	the	pial	surface	[44].
RG start	expressing	astroglial	markers, such	as	the	astrocyte-speciﬁc	glutamate	trans-
porter	(GLAST),	brain	lipid-binding	protein	(BLBP),	and	Tenascin	C (TN-C).	Primate
RG cells	also	express	the	intermediate	ﬁlament	protein, glial	ﬁbrillary	acidic	protein
(GFAP),	which, however, is	absent	in	rodent	and	chick	RG cells	[10]. RG will	give
rise	to	all	major	cell	types	of	the	central	nervous	system, and	are	often	referred	to	as
the	stem	cells	of	the	developing	brain.
Neuroepithelial	and	radial	glia	cells	display	a	complex	mitotic	behavior	know	as
interkinetic	nuclear	migration	(INM).	INM is	characterized	by	migration	of	the	cell
nucleus	during	the	distinct	phases	of	the	cell	cycle: Nuclei	undergoing	S phase	form
a	layer	away	from	the	ventricle	(still	within	the	VZ,	though), while	nuclei	in	M phase
are	aligned	at	the	ventricular	surface	[48]. The	functional	signiﬁcance	of	this	INM
remains	elusive.
RG cells	divide	mostly	asymmetrically2 to	generate	a	wide	variety	of	different	neu-
rons	ﬁrst, at	later	stages	astrocytes	and	even	later	stages	oligodendrocytes. Figure 2
shows	a	schematic	representation	of	the	temporary	distinct, yet	overlapping, phases
of	 neuronal	 and	 glial	 differentiation	 in	 the	mammalian	 neocortex. During	 each
asymmetric	division	a	RG cell	produces	a	new	RG cell	 (i.e. self	 renewal)	and	a
neuron	or	basal	progenitor	(BP) cell3, which	can	further	divide	symmetrically	be-
fore	ﬁnal	differentiation	(Figure 3 illustrates	symmetric	and	asymmetric	divisions	of
RG and	BPs	during	neocortical	development). In	this	way, RG can	specify	during
neocortical	development	to	produce	all	the	different	neuronal	subtypes, astrocytes,
and	oligodendrocytes. While	fate-mapping	and	clonal	experiments in	vitro and in
vivo [78]	have	revealed	that	RG cells	can	indeed	be	multipotent, more	speciﬁed	RG
cells, giving	rise	to	only	neurons	or	glia, have	also	been	observed	[97]	and	it	cannot
be	excluded	that	both	types	co-exist in	vivo. Recent	studies	support	the	notion	that
RG cells	might	be	heterogenous	regarding	their	offspring	producing	capacities	and
fate	potential. For	instance, Franco	et al. [28] identiﬁed	Cux2	positive	RG cells	in
the	developing	murine	neocortex	that	are	intrinsically	speciﬁed	to	only	give	rise	to
upper	layer	neurons. Moreover, other	types	of	RG,	or	RG like	cells	distinct	from	the
2symmetric	divisions	of	RG have	been	described	[62], but	are	rare	and	their	relevance	is	unknown
(they	presumably	produce	two	new	RG cells	[39])
3also	known	as	intermediate	progenitor	cells	or	non-surface	dividing	cells
5
ones	described	above	have	been	described. For	instance, short	neural	precursors
(SNP) were	identiﬁed	as	morphologicaly	distinct	cells	which	are	in	contact	with	the
ventricular	surface	with	their	apical	process	but	possess	basal	processes	that	termi-
nate	in	the	VZ or	sub-ventricular	zone	(SVZ,	see	below)	rather	then	elongating	to	the
pial	surface	[36]. Another	type	of	RG reported	are	basal	RG4,	which	lack	an	apical
process	[36, 55, 66]. They	are	rarely	found	in	mice, but	more	abundant	in	ferret
and	human	neocortex. However, the	link	between	gyrencephaly	and	bRG remains
uncertain	[36].
Neurons Astrocytes Oligodendrocytes
in vivo
development
E8 E10 E11 E12 E13 E15 E16E14 E17 E19E18 E20 P1 P7P3 P9P5 P11 P13 P15 P17
Figure 2: Timing of neuronal and glial development in the neocortex. Modiﬁed from Sauvageot
and Stiles [75]. The waves of subsequent generation of neurons, astrocytes, and oligodendrocytes
are illustrated in correlation to the time of embryonic (E8 – E20 [=birth]) and post-natal (P1 – P17)
development.
Early	 in	cortical	development, asymmetrical	divisions	of	RG lead	 to	self	 renewal
and	generation	of	a	post	mitotic	neuron. Throughout	the	majority	of	neocortical	de-
velopment, however, asymmetric	RG division	does	not	produce	a	post	mitotic	cell
but	rather	a	restricted	progenitor	cell	that	can	further	proliferate	before	ﬁnal	differ-
entiation. These	cells	are	referred	to	as	intermediate	or	basal	progenitors	(IP or	BP,
respectively). They	are	characterized	by	certain	morphological	and	molecular	prop-
erties. BPs	do	not	extend	apical	or	pial	processes	to	contact	the	ventricular	or	pial
surface, respectively	[48]. After	their	generation	they	populate	a	proliferative	zone
adjacent	to	the	VZ,	the	so-called	subventricular	zone	(SVZ).	There, BPs	proliferate
one	to	two	more	times	via	symmetric	divisions	[48]	and	then	differentiate	into	post
mitotic	neurons. This	additional	expansion	of	the	progenitor	pool	allows	to	generate
the	enormous	amounts	of	neurons	populating	the	neocortex. BPs	express	many	of
the	same	markers	as	RGs, such	as	Nestin, but	also	distinct	molecules, such	as	the
T-box	transcription	factor	Tbr2	[23, 37, 77].
Embryonic	neural	progenitor	cells	(eNPCs, i.e. RGs	and	BPs)	become	more	restricted
4also	called	outer	or	intermediate	RG
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Figure 1
Glial nature of neural stem cells (NSCs) in development and in the adult. Neuroepithelial cells in early development divide
symmetrically to generate more neuroepithelial cells. Some neuroepithelial cells likely generate early neurons. As the developing brain
epithelium thickens, neuroepithelial cells elongate and convert into radial glial (RG) cells. RG divide asymmetrically to generate
neurons directly or indirectly through intermediate progenitor cells (nIPCs). Oligodendrocytes are also derived from RG through
intermediate progenitor cells that generate oligodendrocytes (oIPCs). As the progeny from RG and IPCs move into the mantel for
differentiation, the brain thickness, further elongating RG cells. Radial glia have apical-basal polarity: apically (down), RG contact the
ventricle, where they project a single primary cilium; basally (up), RG contact the meninges, basal lamina, and blood vessels. At the end
of embryonic development, most RG begin to detach from the apical side and convert into astrocytes while oIPC production continues.
Production of astrocytes may also include some IPCs (see Figure 2) not illustrated here. A subpopulation of RG retain apical contact
and continue functioning as NSCs in the neonate. These neonatal RG continue to generate neurons and oligodendrocytes through
nIPCs and oIPCS; some convert into ependymal cells, whereas others convert into adult SVZ astrocytes (type B cells) that continue to
function as NSCs in the adult. B cells maintain an epithelial organization with apical contact at the ventricle and basal endings in blood
vessels. B cells continue to generate neurons and oligodendrocytes through (n and o) IPCs. This illustration depicts some of what is
known for the developing and adult rodent brain. Timing and number of divisions likely vary from one species to another, but the
general principles of NSC identity and lineages are likely to be preserved. Solid arrows are supported by experimental evidence; dashed
arrows are hypothetical. Colors depict symmetric, asymmetric, or direct transformation. IPC, intermediate progenitor cell;
MA, mantle; MZ, marginal zone; NE, neuroepithelium; nIPC, neurogenic progenitor cell; oIPC, oligodendrocytic progenitor cell;
RG, radial glia; SVZ, subventricular zone; VZ, ventricular zone.
(IPCs). IPCs can generate neurons (nIPCs) or
generate glial cells, including oligodendrocytes
(oIPCs) or astrocytes (aIPCs) (Figure 1). The
termglial cell becomes somewhat confusing be-
cause it refers to both a progenitor population as
well as a differentiated population of parenchy-
mal astrocytes, oligodendrocytes, and ependy-
mal cells (as discussed below, this problem also
applies to the term astrocyte). However, at least
some of the functions attributed to terminally
differentiated astrocytes (supporting neuronal
function and regulating metabolic activity) are
IPC: intermediate
progenitor cell
nIPC: intermediate
progenitor cell that
generates neurons
oIPC: intermediate
progenitor cell that
generates
oligodendrocytes
likely represented in the adult and earlier pro-
genitor cells including RG. Short of proposing
an entirely new nomenclature, which could add
confusion, we use the term glia more generally
to refer both to glial cells that have specialized
traditional glial functions and to those that, in
addition, retain progenitor capacity.
Many recent publications have described
molecular pathways that regulate ventricular
zone (VZ) and subventricular zone (SVZ)
progenitors as well as progress characterizing
NSCs in vitro. Here we mention some of this
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Figure 3: Modes of division of NPCs duri g eocortical d velopment. Tak n from Kriegstein and
Alvar z-Buylla [48]. RG can divide symmetrically (red arrows) and asymmetrically (blue arrows), while
other progenitors only divide symmetrically. NE = neuroepithelium; MZ = marginal zone; VZ = ven-
tricular zone; SVZ = subventricular zone; MA = mantle zone; oIPC = oligodendrocyte intermediate
prog nitor cell; nIPC = neuronal intermediate progenitor cell.
s	developme t	proceeds. While	RGs	of	the	early	d veloping	brain	are	able	t 	pro-
du e	early	a d	late	born	neurons	(see	below), RGs	of	later	stages	c n	only	generate
late	b rn	neurons. This	multipote t	capacity	restricted	b 	ti e	of	devel pment	was
demonstrated	with	heterotransplant	experiments	[33]. However, the	coexistence	of
multipotent	and	clonally	more	restricted	progenitor	populations	is	not	excluded	by
these	observations.
The	ﬁrst	neurons	to	be	generated	during	neocortical	development	form	the	preplate
and	differ tiate	to	Cajal-R tzius	an 	subpl te	neurons	(SPN).	Following	waves	of
migrating	neurons	then	split	the	preplate	into	the	marginal	zone	and	subplate. Cajal-
Retzius	cells	 form	the	outer	most	neuronal	 layer	during	development	and	are	re-
qui d	for	pr per	positioni g	 f	the	following	waves	of	neu ons	i 	the	c rtical	plate
(CP).	The	six	layers	of	the	CP (layer I –	VI) are	formed	in	an	inside-out	manner, i.e.
newly	differentiating	neurons	migrate	through	already	established	layers	to	form	new
ones	on	top. Hence, layer	VI neurons	are	early	born, while	layer	II/III neurons	are
late	born. Figure 4 illustrates	 the	development	of	 the	neocortex	with	 its	six	neu-
ronal	 layers	 in	 the	CP,	as	well	as	other	structures. After	 formation	of	 the	prelate,
the	next	wave	of	neurons	(born	around	E11.5)	mainly	contains	layer	VI corticotha-
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lamic	projection	neurons	(CThPN),	followed	by	layer	V subcerebral	projection	neu-
rons	(SCPN,	born	around	E13.5), and	layer	IV granule	neurons	(GN,	born	around
E14.5). Callosal	projection	neurons	(CPN) which	start	being	produced	around	E12.5
–	concurrently	with	CThPN and	SCPN –	migrate	to	deep	layers, while	those	born
between	E14.5	and	E16.5	migrate	to	superﬁcial	cortical	layers	(see	Greig	et al. [33]
for	a	review	on	neocortical	projection	neuron	speciﬁcation). Newly	born	neurons
use	various	mechanisms	to	migrate	to	their	ﬁnal	positions. During	early	develop-
ment, they	mainly	use	somal	translocation	to	form	the	prelate. Later, the	majority
of	neurons	migrates	along	the	pial	extensions	of	RGs, that	functions	as	a	scaffold	for
them. During	the	ﬁnal	positioning	neurons	disattach	from	RG processes	and	again
use	somal	translocation	[48].
Beside	excitatory	neurons	generated	from	RG in	the	neocortex, GABAergic	interneu-
rons	generated	from	RG in	the	subpallium	(ventral	telencephalon)	also	populate	the
neocortex. Theses	neurons	arrive	in	the	neocortex	via	various	routes	and	emerge
from	distinct	 locations	 in	 the	subpallium: First, around	E11.5	 in	 the	mouse, tan-
gentially	migrating	cells	origin	from	the	medial	ganglionic	eminences	(MGE) and
the	anterior	entopeduncular	area	(AEP).	They	migrate	superﬁcially	to	the	striatum
and	 invade	 the	cortical	marginal	zone	and	subplate	 [56]. At	E12.5	–	E14.5, the
MGE seems	to	be	the	principle	source	of	these	cells, and	now	a	superﬁcial, as	well
as	a	deep	(i.e. closer	to	the	ventricle)	route	is	used	by	migrating	cells	to	populate
both	the	SVZ /	lower	intermediate	zone	(IZ) and	the	subplate. Later, around	E14.5	–
E16.5, cells	that	migrate	tangentially	into	the	neocortex	seem	to	derive	from	both	the
lateral	ganglionic	eminences	(LGE) and	MGE and	follow	a	deep	route	[56]. GABAer-
gic	interneurons	in	the	neocortex	are	derived	from	cells	that	express	Dlx	genes, and
other	transcription	factors	important	for	subpallium	speciﬁcation, such	as	Nkx2.1
and	Gsh2	[56].
After	neurons	for	all	six	layers	are	generated, RG cells	start	transforming	to	astrocytes
and	later	oligodendrocyte	progenitors	[48]. The	ﬁrst	astrocytes	emerge	around	E16
in	 the	mouse	neocortex, however, the	majority	 is	 formed	 just	before	birth. After
the	last	neurogenic	divisions, RG disattach	from	the	ventricular	and	pial	surface	and
translocate	towards	the	cortical	plate. Some	astrocytes	generated	from	RG transfor-
mation	undergo	another	round	of	symmetric	division	before	ﬁnal	differentiation	and
thus	represent	an	astrocyte	intermediate	progenitor	(aINP).	Interestingly, it	seems	like
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begin to differentiate into radial glia, establishing the 
ventricular zone (VZ)15. Radial glia, in turn, give rise to 
additional progenitor classes, including outer radial glia 
and intermediate progenitors, which together form the 
subventricular zone (SVZ)16,17.
Each of these progenitor populations has distinct 
morphological properties and follows a specific pattern 
of cell division. Radial glia span the thickness of the 
cortex, from the ventricular (apical) surface to the pial 
(basal) surface, and are used as a scaffold by newly born 
neurons as they migrate into the cortex18. They primar-
ily divide asymmetrically to self-renew, while also giv-
ing rise to outer radial glia, intermediate progenitors 
or neurons19,20. Outer radial glia are also unipolar but 
Figure 1 | Neocortical projection neurons are generated in an ‘inside-out’ fashion by diverse progenitor types in the 
VZ and SVZ. This schematic depicts the sequential generation of neocortical projection neuron subtypes and their 
migration to appropriate layers over the course of mouse embryonic development. a | Radial glia (RG) in the ventricular 
zone (VZ) begin to produce projection neurons around embryonic day 11.5 (E11.5). At the same time, RG generate 
intermediate progenitors (IPs) and outer RG (oRG), which establish the subventricular zone (SVZ) and act as 
transit-amplifying cells to increase neuronal production. After neurogenesis is complete, neural progenitors transition to a 
gliogenic mode, generating astrocytes and oligodendrocytes (not shown). Cajal–Retzius (CR) cells primarily migrate into 
neocortical layer I from non-cortical locations, whereas other projection neurons are born in the neocortical VZ and/or 
SVZ and migrate along radial glial processes to reach their final laminar destinations. b | Distinct projection neuron 
subtypes are born in sequential waves over the course of neurogenesis. The peak birth of subplate neurons (SPN) occurs 
around E11.5, with the peak birth of corticothalamic projection neurons (CThPN) and subcerebral projection neurons 
(SCPN) occurring at E12.5 and E13.5, respectively. Layer IV granular neurons (GN) are born around E14.5. Some callosal 
projection neurons (CPN) are born starting at E12.5, and those CPN born concurrently with CThPN and SCPN also migrate 
to deep layers. Most CPN are born between E14.5 and E16.5, and these late-born CPN migrate to superficial cortical 
layers. Peak sizes are proportional to the approximate number of neurons of each subtype born on each day. NE, 
neuroepithelial cell.
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Figure 4: Neuronal subtype development in the neocortex. Modiﬁed from Greig et al. [33]. Timed
generation of neuronal subtypes by radial glia (RG) and intermediate progenitors (IP) (a). Illustration of
main production phas s of various neuro s (b). C = Cajal Retzius c lls, NE = neuroepethelial cells,
RG = radial glia cells, oRG = outer radial glia cells, IP = intermediate progenitor (basal progenitor),
SPN = sub plate neuron, CThPN = corticothalamic projection neur n, SCPN = subcerebral projection
neuron, CPN = callosal projection neuron
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also	astrocytes	populate	the	cortex	in	an	inside	out	manner, similar	to	neurons	(see
above)	[48]. The	ﬁrst	oligodendrocytes	arrive	in	the	neocortex	around	E16	in	the
mouse. They	are	produced	by	Nkx2.1+ precursor	cells	in	the	VZ of	the	medial	gan-
glionic	eminences	(MGE) in	the	ventral	telencephalon	and	migrate	tangentially	into
the	neocortex, similar	to	GABAergic	neurons. Later, after	E18, Emx1+ precursors,
presumably	in	the	dorsal	cortex	itself, produce	another	wave	of	oligodendrocytes.
Interestingly, most	of	the	early	born	oligodendrocytes	die	after	birth, leaving	mainly
Emx1	derived	cells	in	the	adult	brain. Apart	from	neurons, astrocytes, and	oligoden-
drocytes, RGs	will	differentiate	to	ependymal	cells	which	are	lining	the	ventricles
and	some	RGs	will	 remain	 in	 the	adult	brain	 to	 functions	as	adult	neural	 stem	 /
progenitor	cells	(see	section 1.4.1).
1.3.2 Regulation	of	cortical	development
Over	the	many	decades	of	studying	brain	development, many	key	molecules	and
regulatory	pathways	crucial	 for	proper	NPC proliferation	and	differentiation	have
been	identiﬁed. A complete	review	of	the	major	signaling	pathway	discovered	on
brain	development	would	be	beyond	 the	 scope	of	 this	 thesis. However, a	 brief
summary	of	the	most	important	and	well	studied	molecules	and	pathways	is	given
below, with	emphasis	on	molecules	known	to	be	connected	to	ANKHD1	function.
As	mentioned	above, during	early	speciﬁcation	of	the	telencephalon, the	main	sig-
naling	molecules	 include	 the	ﬁbroblast	 growth	 factor	 (FGF) ligands, Wnts, bone
morphogenic	proteins	(BMPs), and	sonic	hedgehog	(SHH).	These	molecules	are	not
only	expressed	in	speciﬁc	centers	during	telencephalic	speciﬁcation	(see 1.3), but
also	function	in	other	phases	of	neural	progenitor	differentiation	and	brain	develop-
ment. Other	secreted	molecules	known	to	be	involved	in	neocortical	development
include	epidermal	growth	 factor	 (EGF),	platelet-derived	growth	 factor	 (PDGF),	as
well	as	 the	 interleukin-6	 (IL-6)	 family	of	cytokines	 (including	 leukemia	 inhibitory
factor	(LIF) and	ciliary	neurotrophic	factor	(CNTF)).
The	Notch	signaling	pathway	plays	a	fundamental	role	in	the	regulation	of	neural
progenitor	cell	development	[14]. It	is	involved	in	numerous	binary	fate	choices	dur-
ing	differentiation	of	cells	in	the	neocortex. For	instance, active	Notch	signaling	in	a
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cell	inhibits	differentiation	from	progenitors	to	neurons, from	oligodendrocyte	pro-
genitor	cells	(OPCs)	to	oligodendrocytes, and	promotes	differentiation	to	astrocytes
[54]. In	mammals	 there	are	 four	receptors	 (Notch1–4), and	ﬁve	classical	 ligands
(Delta-like1, 3, 4	and	 Jagged1, 2), all	of	which	are	 transmembrane	proteins	 that
permit	signaling	between	adjacent	cells	through	direct	contact. Upon	activation	of
the	Notch	receptor	a	series	of	proteolytic	events	eventually	release	the	intracellu-
lar	domain, allowing	it	to	translocate	to	the	nucleus	[54]. There, it	associates	with
transcriptional	co-regulators, such	as	CBF1/RBPjκ and	mastermind, to	activate	gene
transcription. Target	genes	of	Notch	signaling	in	the	vertebrate	nervous	system	are
mainly	 the	basic	helix-loop-helix	 (bHLH) transcriptional	 repressors	hairy	and	en-
hancer	of	split	 (HES) and	HES related	 (HESR/HEY) family	genes	 (especially	Hes 1
and	Hes 5)	[54].
Basic	helix-loop-helix	transcription	factors	(bHLH TFs)	are	important	regulators	of
brain	 development. Apart	 from	 the	 aforementioned	 repressor-type	bHLH genes,
a	 plethora	 of	 proneuronal	 bHLH TFs, including	Neurogenin 1	 and	 2	 (Ngn1, 2),
Achaete	scute-like	1	(Ascl1	/	Mash1), atonal	homolog	1	(Atoh1	/	Math1), and	hairy
and	 enhancer	 of	 split	 6	 (Hes6), promote	 and	 guide	 differentiation	 into	 neurons.
These	pro	neuronal	bHLH factors	dimerize	with	ubiquitously	expressed	bHLH genes,
such	as	E47, and	subsequently	translocate	to	the	nucleus	where	they	bind	to	E-box
sequences	and	activate	transcription	of	target	genes	[44, 100]. Repressor-type	bHLH
factors	inhibit	neuronal	differentiation	in	two	ways: On	one	hand	they	repress	tran-
scription	of	pro	neuronal	genes	by	binding	to	N-box	sequences	and	recruiting	co-
repressors	like	Groucho	[43]. On	the	other	hand, they	dimerize	with	pro	neuronal
bHLH factors	and	thus	prevent	their	transcriptional	activity	[44]. Recently, the	NF-
κB pathway	was	shown	to	be	important	for	neural	progenitor	maintenance, at	least
in	part	through	an	antagonistic	interaction	with	the	proneuronal	bHLH factor	Hes6
[57].
Two	main	signaling	pathways	have	been	identiﬁed	to	be	crucial	for	neuronal	and
glial	differentiation: The	proneural	basic	helix-loop-helix	(bHLH) neurogenic	path-
way, and	Janus	kinase	signal	transducers	and	activators	of	gene	transcription	(Jak-
Stat)	gliogenic	signaling	[16]. As	mentioned	above, many	bHLH factors	are	regu-
lated	directly	or	indirectly	through	Notch	signaling. In	addition, MEK-ERK (mitogen-
activated	or	extra-	cellular	signal	regulated	protein	kinase	kinase	and	its	target	extra-
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cellular	signal	regulated	protein	kinase)	signaling	promotes	generation	of	neurons
during	telencephalic	development	[16]. The	JAK-STAT pathway	is	mainly	inactive
during	early	phases	of	neocortical	development, when	neurons	are	generated. Ac-
tivation	of	 the	 JAK-STAT pathway	 is	crucial	 for	 the	 switch	 to	gliogenesis. Beside
cell	intrinsic	mechanisms, cytokines	acting	through	the	gp130	receptor	can	activate
JAK-STAT signaling.
Moreover, the	nonreceptor	protein-tyrosine	phosphatase	SHP2	was	shown	to	be	im-
portant	in	neural	progenitor	proliferation	and	fate	decisions	[16]. Interestingly, it	can
modulate	not	only	the	neurogenic	(MEK-ERK),	but	also	the	gliogenic	(gp130-JAK-
STAT) signaling	pathway	by	promoting	MEK-ERK signaling	while	simultaneously	in-
hibiting	gp130-JAK-STAT signaling, respectively. In	SHP2-deﬁcient	mice, the	num-
ber	of	cells	positive	for	the	neuronal	marker	TuJI are	reduced, and	an	increased	in
the	number	of	cells	positive	for	the	astrocytic	marker	GFAP was	observed	[45]. Ke
et al. [45] also	found	that	SHP2	deﬁciency	results	in	decreased	proliferation	of	NPCs
in	the	developing	cerebral	cortex.
1.4 Neural	progenitors	in	the	adult	brain
After	completion	of	development, neural	progenitors	persist	in	the	adult	organism.
Their	activity	in	the	adult	brain, however, varies	signiﬁcantly	between	species. For
instance, birds	retain	RG like	cells	in	their	ventricular	zones, and	these	cells	prolif-
erate	and	constantly	add	new	neurons	throughout	most	of	the	telencephalon	[5]. In
poikilotherms, widespread	adult	neurogenesis	persists	and	is	associated	with	con-
stant	brain	growth	[31]. In	most	animals	studied	to	this	day, however, the	majority	of
NPCs	are	lost	at	the	end	of	development, and	neurogenesis	in	the	adult	is	restricted
to	certain	regions. In	mammals, these	regions	are	the	SVZ of	the	lateral	ventricles
and	the	dentate	gyrus	of	the	hippocampus	(see	next	section). However, cells	with
proliferative	capacity	and	the	ability	to	differentiate	to	certain	cells	types	of	the	CNS
have	also	been	found	outside	of	these	regions. For	instance, quiescent	OPCs	–	pre-
sumably	originate	from	embryonic	and	adult	SVZ progenitors	–	are	found	throughout
the	brain	and	can	be	stimulated	to	divide	symmetrically	and	to	differentiate	[70].
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1.4.1 Adult	neurogenesis	in	mammals
Neurogenesis	 in	mammals	was	 traditionally	viewed	to	only	occur	during	embry-
onic	and	perinatal	development	[60]	and	therefor	no	neuronal	regeneration	to	be
present	in	the	adult	brain. Pioneering	work	of	Altman	and	colleagues	in	the	1960s
and	70s	provided	ﬁrst	evidence	for	newly	generated	cells	 in	the	dentate	gyrus	of
the	hippocampus	[4]. Following	the	introduction	of	the	nucleotide	analog	bromo-
deoxyuridine	(BrdU) as	a	lineage	tracer	for	proliferating	cells, lifelong	neurogenesis
in	almost	all	mammals	examined	could	be	demonstrated	[60]. First	evidence	for
adult	neurogenesis	 in	humans	stems	from	work	by	Eriksson	et al. [25] in	the	late
1990s.
In	the	adult	brain	of	mammals, neurogenesis	persists	in	two	regions: the	subven-
tricular	zone	(SVZ) of	the	lateral	ventricles, and	the	dentate	gyrus	(DG) of	the	hip-
pocampus. In	both	niches	more	quiescent	stem	cells	give	rise	to	a	transit	amplifying
cell	population	which	in	turn	produce	neuroblasts	that	migrate	to	their	destinations
and	differentiate	to	neurons.
In	the	SVZ,	NPCs	produce	neuroblasts	that	migrate	along	the	rostral	migratory	stream
to	reach	the	olfactory	bulbs, where	they	differentiate	into	interneurons. NPCs	in	the
SVZ are	heterogeneous: According	to	their	location	in	the	SVZ they	are	restricted
to	give	 rise	 to	certain	neurons	 (e.g. NPCs	 in	 the	dorsal	SVZ generate	 superﬁcial
granule	cells	and	tyrosine	hydroxylase-positive	periglomerular	cells, while	NPCs	in
the	ventral	SVZ generate	deep	granule	cells	and	calbindin-positive	periglomerular
cells)	[40].Transcription	factor	expression	in	the	various	regions	of	the	SVZ resembles
that	involved	in	regional	speciﬁcation	of	the	developing	brain. Beside	neurons, also
oligodendrocytes	are	produced	from	SVZ NPCs, although	to	a	much	lower	extend.
In	the	DG of	the	hippocampus, NPCs	give	rise	to	neurons	and	astrocytes, but	only
very	 few, if	 any, oligodendrocytes. The	 radial	 glia	 like	NPCs	 are	 located	 in	 the
subgranular	zone	of	the	DG,	bordering	the	hilus	of	the	hippocampus. They	are	mul-
tipotent	[7, 8]	and	generally	give	rise	to	transit	amplifying	cells	that	differentiate	into
neuroblasts	and	ﬁnally	dentate	granule	neurons. New	neurons	only	migrate	short
distances, settling	in	the	inner	granule	cell	layer	of	the	DG,	where	they	are	also	func-
tionally	integrated	(For	in	depth	reviews	on	adult	neurogenesis	in	the	DG see	Ming
and	Song [60], and	Bonaguidi	et al. [7]). Adult	neurogenesis	in	the	DG has	been
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shown	to	be	 important	 for	several	brain	 functions, such	as	 learning	and	memory
[18].
Both	intrinsic	and	extrinsic	mechanisms	regulate	different	aspects	of	adult	neuroge-
nesis	[60]. Many	intrinsic	signaling	pathways	are	conserved	from	embryonic	brain
development, which	is	not	surprising	given	the	similarities	between	embryonic	and
adult	NPCs. Extrinsic	signals, however, can	differ	signiﬁcantly	due	to	the	changed
environment	compared	to	the	embryonic	situation. Some	of	the	conserved	path-
ways	include	Notch, Wnts, BMPs, and	SHH signaling. Transcription	factors	such
as	Pax6, Tbr2, Sox, or	NeuroD are	as	well	conserved	and	important	regulators	of
adult	NPCs	function. Signaling	mechanisms	in	adult	neurogenesis	are	reviewed	in
depth	by	Faigle	and	Song [26]. Recent	additions	to	signaling	components	in	adult
NPCs	include	the	orphan	receptor	tailless	(TLX) [80]	and	the	tumor	necrosis	factor
receptor	superfamily	member	6	(TNFRSF6	/	Fas	/	CD95)	[15]. Both	proteins	seem
not	to	be	required	for	NPC function	during	brain	development, and	thus	represent
a	distinguishing	feature	of	adult	NPCs.
1.4.2 Neural	progenitor	cells	and	the	origin	of	brain	tumors
In	 the	brain, cancers	of	many	different	 types	can	arise	 following	deregulation	of
cells	due	to	mutations. Gliomas	are	the	most	common	type	of	brain	tumors, among
which	glioblastoma	multiforme	(GBM),	are	the	most	devastating	and	patients	have
a	dismal	prognosis.
Until	 recent	years	 (the	 late	2000s)	 somatic	mutations	 in	differentiated	cells	were
predominantly	perceived	as	the	origin	of	gliomas. However, in	recent	years, more
and	more	evidence	suggests	that	neural	stem	/	progenitor	cells	might	be	the	cells
of	origin	 for	many	 tumors	 in	 the	brain	 [reviewed	 in 2, 73, 98]. Adult	NPCs	use
many	of	the	signaling	pathways	deregulated	in	cancers. Discussing	the	cell	of	ori-
gin	of	brain	tumors, it	is	crucial	to	discriminate	between	the	cell	in	which	the	ﬁrst
oncogenic	hit	occurs	and	the	cell	that	eventually	has	the	capacity	to	develop	to	a
tumor. For	instance, an	oncogenic	hit	may	occur	in	a	stem	cell, but	only	a	certain,
more	differentiated	progenitor	might	have	the	ability	to	transform	to	a	tumor. in-
deed, using	lineage	tracing	by	MADM,	Liu	et al. [53] have	provided	evidence	for
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this	theories: They	demonstrated	that	(i)	oncogenic	hits	in	progenitor	cells	are	re-
quired	for	 tumor	initiation, and	(ii)	only	OPCs	(that	either	acquire	 the	oncogenic
mutations	themselves	or	inherit	them	from	aNPCs)	can	form	gliomas	in	a	p53	/	Nf1
mouse	model.
As	a	complementary in	vitro approach	 to	assess	stem	cell	 features, NPCs	can	be
grown	in	so	called	”neurospheres”	in	serum-free	media	supplemented	with	growth
factors. Similarly, cancer	cells	from	GBM patients	have	been	isolated	and	grown
in	spheres	under	serum-free	conditions. These	sphere-cultures	resemble	 those	of
”normal”	NPCs	in	many	regards, can	act	as	tumor-initiating	cells, and	establish	tu-
mors	that	closely	resemble	the	main	histologic, cytologic, and	architectural	features
of	 the	human	disease, even	when	challenged	 through	serial	 transplantation	[30].
Taken	together, there	is	strong	evidence	for	a	crucial	role	of	aNPC in	brain	tumor
development.
1.5 The	Ankyrin	repeat	and	KH domain-containing	protein	1	(ANKHD1)
ANKHD1	 is	 a	 recently	discovered	protein	with	 important	 functions	 in	organ	de-
velopment	 and	 tumor	biology. The	protein	was	ﬁrst	described	 in	Drosophila	by
Smith	et al. [84], where	the	homolog	multiple	ankyrin	repeats	and	single	KH domain
(MASK) has	been	found	to	be	an	important	signaling	component	in	photoreceptor
differentiation. One	year	later, the	ﬁrst	study	describing	ANKHD1	in	human	cells
was	published	by	Poulin	et al. [65]. The	following	sections	will	give	an	introduc-
tion	to	 the	protein	and	summarize	ﬁndings	regarding	its	 functions	 in	normal	and
neoplastic	tissue. Naming	of	this	protein	in	the	literature	is	inconsistent. Through-
out	this	thesis, and	in	compliance	with	the	HUGO Gene	Nomenclature	Committee
[90]	for	human	genes, and	the	International	Committee	on	Standardized	Genetic
Nomenclature	for	Mice	[58], the	protein	will	be	referred	to	as	ANKHD1. The	name
MASK will	be	used	for	the	Drosophila	protein	[27].
1.5.1 Discovery, sequence	properties, and	structural	features
In	2002, Smith	et al. [84] identiﬁed	the	hitherto	unknown	protein	MASK in	a	screen
designed	to	study	signaling	components	of	the	protein	tyrosine	phosphatase	Cork-
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screw	(CSW,	SHP2	in	mammals)	in	Drosophila	melanogaster. Cloning	and	sequenc-
ing	revealed	an	approximately	13kb	long	open	reading	frame	corresponding	to	the
mask gene. The	genomic	locus	of mask spans	18kb	and	encodes	for	a	protein	of
4001	amino	acids, and	a	predicted	mass	of	423 kDa. The	MASK protein	contains
known	structural	motifs: two	blocks	of	ankyrin	repeats	and	a	single	KH domain	[84].
Both	motifs	are	found	in	a	large	number	of	other	proteins.
The	ankyrin	repeat	(ANK) is	one	of	the	most	common	protein	sequence	motifs. It
was	discovered	in	1987	by	Breeden	and	Nasmyth [9], who	reported	a	33	residue
repeating	motif	in	the	two	yeast	cell-cycle	regulators, Swi6p	and	Cdc10p, and	in
the	Notch	and	LIN-12	developmental	regulators	from	Drosophila	melanogaster	and
Caenorhabditis	elegans	[76]. Ankyrin	repeats	have	been	discovered	in	a	myriad	of
proteins	with	various	functions. A sequence	homology	analysis	study, based	on	the
non-redundant	SMART protein	database, has	shown	that	there	are	19276	ankyrin
repeat	sequences	in	3608	proteins	[76]. These	ankyrin	sequences	have	been	de-
tected	in	organisms	ranging	from	viruses	to	humans, however	most	of	them	were
found	in	eukaryotic	proteins, located	in	both	intra-	and	extracellular	compartments.
Ankyrin	repeat	proteins	mediate	protein–protein	interactions	and	have	been	shown
to	be	involved	in	many	biological	processes, including	transcriptional	regulation,
cytoskeletal	organization, modulation	of	cell	cycle	progression, cell	development,
and	differentiation	[52]. The	ANK motif	contains	certain	key	residues	which	are
conserved	despite	the	degeneration	of	other	repeating	sequences. These	patterns
of	conserved	residues	ensure	structural	 integrity	of	 the	motif. For	 instance, three
glycine	residues	are	conserved	at	consensus	positions	4, 15	and	27, and	the	charac-
teristic	Thr-Pro-Leu-His	(TPLH) tetrapeptide	motif	forms	a	tight	turn	and	initiates	the
ﬁrst	alpha-helix	of	the	ANK repeat	[76]. Ankyrin	repeats	exhibit	a	helix-loop-helix
structure. The	two	alpha-helices	are	arranged	in	an	anti-parallel	fashion, and	repeats
are	connected	by	beta	hairpin	motifs	that	project	away	from	the	helices	in	an	nearly
90	degree	angle	[52].
The	K homology	(KH) domain was	ﬁrst	discovered	in	–	and	named	after	–	the	het-
erogeneous	nuclear	ribonucleoprotein	(hnRNP) K by	Siomi	et al. [83] in	1993. The
motif	is	a	conserved	sequence	of	around	70	amino	acids. The	KH domain	can	bind
RNA or	 single	 stranded	DNA and	 is	 found	 in	a	myriad	of	proteins	 involved	 in	a
wide	variety	of	biological	processes, including	splicing, transcriptional	regulation,
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and	translational	control	[95]. All	KH domains	share	a	”minimal	consensus	motif”
in	their	linear	sequence, but	their	three	dimensional	structure	can	vary. Two	types
of	KH domains	have	been	described	[34]: Type I domains	form	a	beta-alpha-alpha-
beta-beta-alpha	structure, while	 type II domains	consist	of	alpha-beta-beta-alpha-
alpha-beta	modules. All	beta	strands	run	anitparallel	in	type I domains, while	two
beta-strands	run	parallel	in	type II domains. Type I KH domains	are	usually	found	in
eukaryotes, while	type II domains	are	mostly	found	in	prokaryotes	[95]. The	binding
occurs	in	a	cleft	formed	between	alpha	helix	1, alpha	helix	2, the	highly	conserved
GXXG loop, and	a	variable	 loop. The	binding	cleft	can	only	accommodate	 four
bases	of	the	binding	nucleotide. Proteins	often	contain	multiple	KH motifs, which
can	 function	 independently	or	cooperatively	 [95]. However, some	proteins	only
contain	a	single	KH domain, including	Mer1p, Sam68, and	ANKHD1. Fragile	X
mental	retardation	protein	(FMRP) contains	two	KH domains, and	loss	of	function
mutations	therein	have	been	associated	with	the	fragile	X mental	retardation	syn-
drome	[51].
In	addition	to	the	ANK and	KH domains, MASK contains	several	long	stretches	of
glutamine	residues	and	a	highly	basic	region. MASK does	not	show	signiﬁcant	ho-
mology	in	sequence	or	overall	structure	to	any	protein	of	known	function	[84].
Orthologs	in	mice	and	humans. In	2003, Poulin	et al. [65] identiﬁed	the	human
and	mouse	orthologs	of	MASK.	Human	ANKHD1	is	located	on	chromosome	5q31.3,
and	mouse	ANKHD1	is	found	on	chromosome	18, in	a	region	syntenic	to	human
5q31. Both	proteins	are	highly	similar	to	each	other, and	both	contain	two	blocks
of	ankyrin	repeats	(25	repeats	in	total)	and	a	single	KH domain. These	domains	are
strongly	conserved	compared	to	MASK,	though	the	overall	proteins	are	shorter	in
human	and	mouse. The	canonical	isoform	of	human	ANKHD1	is	translated	from
a	8139 bp	long	mRNA (consisting	of	a	5’-UTR of	60	bp, an	ORF of	7629	bp, and
a	3’-UTR of	450-bp)	 [65]	and	produces	a	protein	of	2542	amino	acids	 in	 length
(mouse: 2548 aa). A schematic	illustration	of	human	full	length	ANKHD1	is	shown
in	Fig. 5.
Several	splice	variants	and	isoforms	of	ANKHD1	have	been	described	or	annotated
in	protein	databases. Poulin	et al. [65] actually	ﬁrst	discovered	an	interesting	vari-
ant	 of	ANKHD1, while	working	on	4E-BP3, a	protein	 important	 for	 translational
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Figure 5: The human ANKHD1 protein. Ankyrin repeats and KH domain are drawn in dark grey in
correct proportion the complete sequence. Numbers indicate amino acid positions.
control, and	located	just	downstream	of	the Ankhd1 genomic	locus. The	authors
showed	that	ANKHD1	and	4E-BP3	loci	can	produce	a	single, approximately	8.5 kb
long	transcript, that	codes	for	a	”fusion	protein”	of	those	two	genes. Moreover, exon
B from	4E-BP3	in	this	fusion	protein	is	translated	in	an	alternative	reading	frame. The
resulting	protein	was	designated	MASK-BP3ARF [65]. Both	gene	fusion	and	usage	of
alternative	reading	frames	are	rare	in	humans, and	MASK-BP3	its	the	ﬁrst	instance
were	both	mechanisms	are	utilized	simultaneously. Miles	et al. [59] identiﬁed	two
variants	of	ANKHD1	which	both	lack	the	KH domain	and	are	signiﬁcantly	shorter,
containing	627	or	435	amino	acids. They	were	shown	to	bind	to	the	HIV1	viral	pro-
tein	R (Vpr)	and	hence	designated	as	Vpr-binding	ankyrin	repeat	protein	(VBARP)
-L or	-S,	respectively. These	variants	seem	to	be	involved	in	cell	survival	signaling
through	regulating	caspases	[59]. Duarte	et al. [22] reported	yet	another	splice	vari-
ant	of	ANKHD1, which	uses	an	alternative	last	exon	(exon 10A).	It	is	signiﬁcantly
shorter	than	the	full	length	ANKHD1	and	was	reported	to	be	upregulated	to	a	higher
extend	than	other	splice	variants	during	erythroid	differentiation	[22]. Finally, the
protein	database	Uniprot	[94]	lists	six	isoforms	for	ANKHD1, one	of	which	corre-
sponds	to	VARBP-L.
ANKHD1	paralogs. One	gene, Ankrd17, has	been	identiﬁed	as	paralog	of	ANKHD1
[65, 99]. Ankrd17, also	known	as	gene	trap	ankyrin	repeat	(GTAR) [38]	and	some-
times	referred	to	as	MASK2	[74, 81], shows	71%	homology	to	ANKHD1, and	seem-
ingly	arose	by	gene	duplication	of	ANKHD1[65]. Ankrd17	has	been	shown	to	be
important	for	liver	development	as	well	as	differentiation	of	hematopoeitic	progen-
itors, and	 is	 essential	 for	 vascular	 integrity	 during	 embryogenesis. Homozygous
knockouts	for	Ankrd17	are	embryonic	lethal	at	embryonic	day	11	(E11)	[38].
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General	expression	pattern. ANKHD1	seems	to	be	expressed	ubiquitously	in	hu-
man	and	mouse	tissues, though	not	many	tissues	have	been	thoroughly	 tested	in
experiments	yet. So	far, ANKHD1	mRNA expression	was	reported	in	several	mam-
malian	tissues, including	the	mouse	brain	[65]. Data	from	microarray	analyses	of
differentiating	aNPCs	suggests	that	ANKHD1	might	be	expressed	in	these	cells	and
regulated	during	 their	differentiation	 (unpublished	data	 from	our	 lab). Moreover,
the	protein	has	been	detected	in	some	human	tissues	and	cell	 lines	(see	sections
4.2 and 4.8 for	an	in	depth	discussion	of	our	ﬁndings	on	ANKHD1	expression	and
comparison	to	literature).
1.5.2 Known	functions	of	ANKHD1	during	development	and	in	adult	tissues
Currently, no	studies	investigating	the	role	of	mammalian	ANKHD1	during	develop-
ment	have	been	published. However, work	in	Drosophila	shows	the	involvement
of	MASK in	normal	tissue	development. Smith	et al. [84] investigated	many mask
mutants	for	their	phenotype. They	concluded	thatmask is	an	essential	gene	because
many	homozygous	and	transheterozygous	mutant	animals	die	during	ﬁrst	instar	lar-
val	development. Work	with	non-lethal	mutants	further	revealed	that	MASK is	re-
quired	for	proper	photoreceptor	differentiation	in	the	eye, as	well	as	cell	proliferation
and	survival. The	mutagenesis	screen	in	which mask was	identiﬁed	was	designed
to	reveal	novel	components	of	receptor	tyrosine	kinase	(RTK) signaling	[84]. The
authors	showed	genetic	interaction	ofmask and	RTK signaling	components, such	as
Sevenless	(SEV),	corkscrew	(CSW),	and	Ras. Their	results	suggest	that	MASK plays
a	positive	role	in	transducing	the	signal	downstream	of	receptor	tyrosine	kinases,
such	as	EGFR.	The	importance	of	MASK for	proper	eye	development	was	recently
conﬁrmed	with	different	methods	by	two	other	groups	[74, 81]. The	same	studies
also	revealed	that	MASK is	required	for	normal	wing	development, as	knockdown	of
mask resulted	in	smaller	wings	[74, 81]. Moreover, both	studies	showed	that	MASK
is	a	co-factor	of, and	interacts	with, YAP,	a	signaling	component	of	the	Hippo	path-
way	important	 for	 tissue	growth. This	 interaction	was	conﬁrmed	in	human	293T
cells. However, only	Sidor	et al. [81] could	observe	translocation	of	ANKHD1	to
the	nucleus	and	DNA binding, and	 thus	a	 function	as	nuclear	co-factor	 remains
controversial. Given	the	conservation	of	the	ANK and	KH domains	in	mammals, it
is	tempting	to	speculate	that	ANKHD1	might	play	an	important	role	in	mammalian
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organ	development.
1.5.3 The	role	of	ANKHD1	in	cancer
In	2006, Traina	et al. [92] reported	a	higher	expression	of	ANKHD1	mRNA in	pri-
mary	acute	leukemia	samples	compared	to	normal	hematopoietic	cells. Moreover,
in	the	same	study, increased	levels	of	ANKHD1	mRNA and	protein	expression	in
leukemia	cell	lines	was	detected	compared	to	normal	hematopoietic	cells. The	hu-
man	 ortholog	 to	Drosophila	CSW,	 the	 nonreceptor	 protein-tyrosine	 phosphatase
SHP2, was	shown	to	be	involved	in	many	leukemias	and	to	be	overexpressed	in
many	 primary	 leukemia	 cells	 and	 in	 leukemia	 cell	 lines. Given	 the	 interaction
of	CWS and	MASK in	Drosophila, Traina	et al. [92] investigated	a	possible	inter-
action	of	SHP2	and	ANKHD1. They	successfully	co-immunoprecipitated	the	two
proteins	in	K562	and	LNCaP cells. The	functional	relevance	of	this	interaction	in
acute	leukemias, however, remains	elusive. In	2012, Dhyani	et al. [19] reported
that	ANKHD1	is	highly	expressed	in	multiple	myeloma	patient	cells	and	cell	lines.
Knockdown	of	ANKHD1	inhibited	proliferation	and	delayed	S to	G2M cell	cycle
progression	[19]. Furthermore, the	authors	observed	an	upregulation	of	cyclin	de-
pendent	kinase	inhibitor	p21	–	irrespective	of	the	p53	status	of	the	multiple	myeloma
cell	lines	–	after	ANKHD1	knockdown. Finally, low	expression	of	ANKHD1	was	cor-
related	with	signiﬁcantly	better	relapse-free	survival	in	two	independent	data	sets	of
breast	cancer	patients	[74]. However, the	probe	used	in	these	data	sets	recognizes
a	sequence	in	the	ﬁrst	ankyrin	repeat	block, and	thus	it	is	not	clear	which	variant	of
ANKHD1 or	even	if	the	MASK-BP3	fusion	protein	are	responsible	for	the	correla-
tion. Together, it	is	tempting	to	speculate	that	ANKHD1	plays	an	cancer	promoting
role	when	it	is	deregulated.
20
1.6 Aim	of	this	thesis
ANKHD1	seems	 to	be	 important	 for	 the	 regulation	of	progenitor	cells	 in	various
tissues	and	is	presumably	expressed	in	the	brain. Moreover, its	 transcript	is	pref-
erentially	loaded	to	ribosomes	during	neuronal	differentiation	of	aNPCs. We	thus
hypothesized	that	ANKHD1	is	expressed	in	embryonic	and	adult	NPCs	and	might
be	important	for	their	functional	regulation. Furthermore, ANKHD1	might	be	dereg-
ulated	in	brain	cancers, similar	to	the	conditions	in	several	leukemias.
The	current	project	aims	at	elucidating	the	function	of	ANKHD1	during	mouse	neu-
ral	 development	 and	 in	 adult	NPCs. First, we	will	 investigate	 the	 expression	of
ANKHD1	in	embryonic	and	adult	NPCs, as	expression	of	ANKHD1	in	NPCs	has
not	been	proven	hitherto. Unpublished	microarray	data	from	our	work	already	sug-
gests	that	its	mRNA transcripts	are	present	in	NPCs. We	will	investigate	mRNA and
protein	levels	in	embryonic	and	adult	NPCS in	various	age	groups	to	clarify	its	ex-
pression	patterns.
To	elucidate	the	role	of	ANKHD1	during	neural	development, we	will	use	the in
utero electroporation	technique	to	perform	loss-	and	gain	of	function	experiments
in	 the	 developing	 embryo	 brain in	 vivo. After	 knockdown	 or	 overexpression	 of
ANKHD1	 in	 radial	glia	cells	we	will	assess	how	 these	cells	and	 their	progenies,
i.e. basal	progenitors	and	neurons, proliferate	and	differentiate	with	various	meth-
ods	and	markers. Moreover, we	will	use	primary	cultures	of	isolated	aNPCs	to	study
the	function	of	ANKHD1	in	these	cells.
Finally, the	inﬂuence	of	ANKHD1	on	glioma	initiating	cells	will	be	assessed. Gliomas
presumably	 originate	 from	mutated	NPCs	 and	 often	 have	 deregulated	 pathways
which	are	important	for	NPC maintenance. We	will	use	primary	cultures	of	isolated
glioma	initiating	cells	to	investigate	how	deregulated	ANKHD1	levels	can	inﬂuence
their	proliferation	phenotype.
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2 Materials	and	Methods
2.1 Materials
2.1.1 Chemicals	and	reagents
Table 2: Chemicals and reagents
Chemical	/	reagent	/	kit manufacturer
-glycerophosphate Sigma
-mercaptoethanol Merck
Acid-Phenol:Chloroform Ambion
Acrylamide	solution Roth
Agarose Sigma-Aldrich
Ammonium	persulphate	(APS) Merck
B27	Supplement Invitrogen
BCA kit Thermo	Fisher
bFGF relia	tech
Boric	acid Fluka
Brome	phenol	blue Merck
Bromo-2-deoxyuridine	(BrdU) Sigma-Aldrich
Complete	protease	inhibitor Roche
Diethyl	pyrocarbonate	(DEPC) Sigma-Aldrich
dNTP mix	(10mM) Fermentas
D(+)-Glucose AppliChem
Dulbeco’s	Modiﬁed	Eagles	Medium	(DMEM) Invitrogen
DNAse Roche
Dispase2 Roche
EGF Promocell
Ethanol Riedel	de	Haen
Eukitt	(Corbit	Balsam) Hecht
Glycine Sigma
Hank’s	balanced	salts	solution	(HBSS) Invitrogen
Ham’s	F12 Invitrogen
Heparin	Cell	Culture	Grade Sigma-Aldrich
HEPES Sigma-Aldrich
Hoechst	33342 Biotrend
Hydrochloric	acid	(HCl) VWR
Continued
23
Table 2: Chemicals and reagents
Chemical	/	reagent	/	kit manufacturer
Isoﬂurane Baxter
Ketavet	(100mg/ml) Pﬁzer
L-Glutamine	(100x	L-Glutamine) Invitrogen
Magnesium	sulfate	(MgSO4) Sigma-Aldrich
mirVana	miRNA Extraction	Kit Ambion
Mowiol Calbiochem
Neurobasal	A Medium Invitrogen
Oligonucleotide	primers MWG
Paraformaldehyde	(PFA) AppliChem
4%	Paraformaldehyde	in	phosphate	buffer Roth
1x	PBS (without	Mg2+	and	Ca2+) PAA
PCR buffer	without	MgCl2	(10x) Applied	Biosystems
PCR H2O Braun
Papain Sigma-Aldrich
Pellet	Paint Novagen, Merck
Penicillin	Streptomycin Invitrogen
Phenyl	methyl	sulfonyl	ﬂuoride	(PMSF) Sigma
P-nitrophenylphosphate Merck
Potassium	chloride	(KCl) Applichem
Potassium	phosphate	monobasic	(KH2PO4) Gerbu
Protein	A/G PLUS-Agarose	beads Santa	Cruz	Biotechnology
RNase-free	H2O Ambion
RNeasy	Mini	Kit Qiagen
Rompun	(2%) Bayer
Sodium	dodecyl	sulfate	(SDS) Roth
Sodium	acide	(NaN3) Merck
Sodium	acetate	(C2H3NaO2; RNase	free) Ambion
Sodium	chloride	(NaCl) Fluka
Sodium	chloride	0.9%	sterile	(NaCl) Braun
Sodium	dihydrogen	phosphate	monohydrate	(NaH2PO4) Roth
Sodium	ﬂuoride	(NaF) Merck
Sodium	hydroxide	(NaOH) Sigma
Sodium	orthovanadate Merck
Sodium	phosphate	dibasic	heptahydrate	(Na2HPO4	·	7H2O) Sigma-Aldrich
Sodium	pyrophosphate Merck
Sodium	pyruvate Invitrogen
Continued
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Table 2: Chemicals and reagents
Chemical	/	reagent	/	kit manufacturer
Sodium	tetraborate	(Borax) Merck
Subcellular	Protein	Fractionation	Kit	for	Cultured	Cells Pierce
SuperFrost	slides Roth, Germany
Superscript	III First-Strand	Synthesis	SuperMix Invitrogen
SYBR®	Green	PCR Master	Mix Applied-Biosystems
TEMED Sigma
Tools	for	mouse	surgery Fine	Science	Tools
Tris	base Sigma-Aldrich
Triton	X-100 Sigma-Aldrich
Trypsin-EDTA (0.05%) Invitrogen
Tween-20 Merck
2.1.2 Buffers	and	media
PBS,	20x Dissolve	160 g/l	NaCl, 23 g/l Na2HPO4, 28.84 g/l NaH2PO4, 4 g/l	 KCl,
4 g/l KH2PO4 in H2O. Adjust	pH to	7.4	with	HCl.
0.2M monobasic	stock	solution Dissolve	27,8 g/l NaH2PO4 in H2O.
0.2M dibasic	stock	solution Dissolve	107,30 g/l Na2HPO4·7H2O in H2O.
0.2M Phosphate	buffer Combine	69ml	of	0.2M monobasic	 and	231ml	of	0.2M
dibasic	stock	solutions	and	adjust	volume	to	300ml	(pH7.3)	with H2O.
aNPC /	GIC medium Neurobasal A Medium	supplemented	with	B27	Supplement
(1x), L-Glutamine	(2mM),	Penicillin/Streptomycin	(Pen: 100	units/ml; Strep:
100 µg/ml), Heparin	(2 µg/ml), bFGF (20 ng/ml), and	EGF (20 ng/ml).
PDD-Solution Papain	(0.01%), Dispase	2	(0.1%), DNAse	(0.01%), MgSO4	(12.4mM)
in	HBSS (without MgCl2 and CaCl). The	solution	is	sterile	ﬁltered	and	stored
in	aliquots	at	-20°C.
cell	lysis	buffer 25mM Tris·HCl	pH8.0, 0.5mM EDTA,	0.5%	Triton	X-100, 150mM
NaCl, 1mM DTT and	1×Complete	Protease	Inhbitor	Cocktail
IP wash	buffer 25mM TRIS pH7.8, 200mM NaCl, 0.5%	Triton	X-100
PBS-Tween 0.1%Tween-20	in	PBS.
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Sample	Buffer 125mM Tris-HCl	(pH7.4), glycine	(200ml/l),
-mercaptoethanol	(100ml/l), SDS (40 g/l), brome	phenol	blue	(50mg/l).
Running	Buffer Tris	base	(10 g/l), glycine	(30.28 g/l), SDS (150 g/l)
Transfer	Buffer Tris	base	(3 g/l), glycine	(14.4 g/l), methanol	(200ml/l)
Lower	Tris	Buffer	(4x) Tris	base	(181 g/l), SDS (4 g/l), 37%	HCl	(135ml/l)
Upper	Tris	Buffer	(4x) Tris	base	(60.6 g/l), SDS (4 g/l)
Running	Gel	(per	10ml) 3.5ml H2O, 2.5ml	Lower	Tris	Buffer, 4ml	of	30%	Acry-
lamide, 10 µl	TEMED,	100 µl	of	10%	APS
Stacking	Gel	(per	10ml) 6.35ml H2O, 2.5ml	Upper	Tris	 Buffer, 1.15ml	of	30%
Acrylamide, 10 µl	TEMED,	100 µl	of	10%	APS
Stripping	Buffer 75mMTris-HCl	(pH6.8), SDS (12 g/l), -mercaptoethanol	(4.68ml/l)
HBS 150mM NaCl, 20mM HEPES,	pH7.4
blocking	solution 5%	normal	donkey	serum	, 0.1%	Triton	X-100, 0.5mg/ml	bovine
serum	albumin	in	HBS.
hybridization	buffer Torula	yeast	tqRNA (1mg/ml), Formamid	(50%), 1x	salt	buffer,
10%	dextran	sulphate	solution, 1x	Denhardts	solution. Mix	in	respective	order
and	adjust	volume	with H2O. Store	at	-20ºC.
10x	salt	buffer 114 g/l	NaCl, 14.04 g/l	Tris	HCl, 1.34 g/l	Tris	Base,
7.8 g/l Na2HPO4•2H2O,7.1 g/l NaH2PO4, 18.61 g/l	EDTA.	Dissolve	in H2O.
100x	Denhardts	solution 20mg/ml	BSA,	20mg/ml	Ficoll, 20mg/ml	polyvinylpyrol-
lidone. Dissolve	in H2O and	store	at	-20ºC.
Dextrane	sulfate	solution Dissolve	0.5 g/ml	in H2O, store	at	4ºC.
ISH wash	solution 1xSSc, 50%	form	amide, 0.1%	Tween20	in	water.
5x	MAB buffer 58 g/l	maleic	acid, 43.5 g/l	NcCl, 38.5 g/l	NaOH in	water. Adjust
pH to	7.5	and	ﬁlter	sterile.
MABT buffer Dilute	5x	MAB buffer	to	1x	and	add	0.1%	Tween20.
2%	DIG-blocking	reagent Dissolve	4 g	DIG-block	in	200ml	MABT (heating	required).
Aliquot	and	store	at	-20ºC.
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ISH staining	buffer 100mM NaCl, 50mM MgCl2, 100mM Tris	pH9.5,
0.1%	Tween20, and	1mM (appr.) Levamisol	in	water	(prepare	fresh).
FP buffer 5%	FCS in	PBS.
SFP buffer 0.1%	Saponin, 5%	FCS in	PBS.
2.1.3 Plasmids
The	pCAG-YFP plasmid	was	obtained	from	Addgene. Human	ANKHD1	open	read-
ing	frame	cDNAwas	purchased	from ’Thermo	Scientiﬁc	Open	Biosystems	ORFeome
Collaboration	Clones	and	Collections’ in	a	pENTR223.1	plasmid	and	 sub-cloned
into	the	pFlag-CMV-D11	plasmid	using	the	gateway	cloning	system	according	to	the
manufacturers	instructions. The	resulting	plasmid	was	termed	pFlag-ANKHD1.
The	 human	ANKHD1	ORF was	 further	 sub-cloned	 into	 the	pCAG-YFP vector	 to
generate	the	N-terminal	tagged	fusion	protein. Conventional	cloning	methods	(i.e.
restriction	enzyme	digest, T4	polymerase	ligation)	were	used	due	to	lack	of	gateway
compatible	recipient	vector. First, a	new	cloning	site	was	inserted	at	the	end	of	the
YFP (removing	the	stop	codon)	in	the	pCAG-YFP plasmid. This	new	site	(MCS2)	con-
tains	a	NotI and	downstream	XhoI restriction	site. The	modiﬁcation	was	introduced
by	cutting	pCAG-YFP with	BsrGI and	NotI,	and	ligating	a	short	sequence	of	annealed
synthesized	oligomeres	with	appropriate	5’	overhangs	and	containing	the	required
restrictions	sites. The	NotI site	used	in	this	step	was	removed	by	altering	bases	in	the
oligomers. Next, the	ANKHD1	insert	was	cut	out	of	pENTR223.1	using	NotI and
SalI restriction	sites	and	inserted	into	the	MCS2	of	the	newly	generated	pCAG-YFP
plasmid	cut	with	NotI and	XhoI.	This	way	ANKHD1	was	inserted	in	frame	on	the	C-
terminal	side	of	YFP,	generating	a	fusion	protein. This	construct	is	hereafter	referred
to	as	pCAG-YFP-ANKHD1.
A C-terminal	truncated	form	of	ANKHD1	lacking	the	KH domain	was	generated	as
follows. First, the	pFlag-ANKHD1	plasmid	was	cut	with	PsyI and	SalI to	remove	the
C-terminus	containing	the	KH domain	and	stop	codon. Then	synthesized	oligomere
containing	a	stop	codon	was	and	appropriate	5’	overhangs	was	inserted	and	ligated,
resulting	in	the	pFlag-ANKHD1-∆C plasmid.
A summary	of	all	cloned	and	used	plasmids	is	shown	in	table 3.
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Table 3: Plasmids
Name Description	/	source
pCAG-YFP Addgene
pFlag-CMV-D11 gateway	destination	vector	with	N-terminal	Flag	tag, DKFZ repository
pFlag-ANKHD1 human	ANKHD1	cloned	into	pFlag-CMV-D11
pFlag-ANKHD1-∆C truncated	ANKHD1	on	C-terminus, KH domain	missing
pYFP-ANKHD1 human	ANKHD1	cloned	into	pCAG-YFP,	generating	YFP tagged	protein
2.1.4 Antibodies
Primary	and	secondary	antibodies	are	described	in	table 4 and 5, respectively.
Table 4: Primary antibodies
Name Species Clonality Manufacturer Concentration
Actin goat polyclonal Santa	Cruz 1:5000	(WB)
Akt rabbit polyclonal Cell	signaling 1:1000	(WB)
Ankhd1 rabbit polyclonal Sigma 1:1000	(WB),	1:200	(IP)
Erk rabbit polyclonal Santa	Cruz 1:1000	(WB)
Flag mouse monoclonal Sigma 1:1000	(WB)
GAPDH mouse monoclonal Santa	Cruz 1:1000	(WB)
GFP chicken monoclonal Aves 1:1000	(WB),	1:200	(IP)
p21 mouse monoclonal Cell	Signaling 1:500	(WB)
pAkt rabbit polyclonal Cell	signaling 1:1000	(WB)
pErk rabbit polyclonal Santa	Cruz 1:1000	(WB)
Satb2 mouse monoclonal Abcam 1:200	(IF)
Tbr2 rabbit polyclonal Abcam 1:500	(IF)
Table 5: Secondary antibodies
Name Manufacturer concentration
goat	anti	chicken	Alexa	488 Dianova 1:500	(IF)
goat	anti	rabbit	Alexa	568 Dianova 1:500	(IF)
goat	anti	mouse	Alexa	633 Dianova 1:500	(IF)
donkey	anti	goat	HRP conj. Santa	Cruz 1:5000	(WB)
goat	anti	mouse	HRP conj. Dianova 1:5000	(WB)
goat	anti	rabbit	HRP conj. Dianova 1:5000	(WB)
28
2.2 Methods
2.2.1 Animals
Animals	were	housed	in	the	animal	facilities	of	the	German	Cancer	Research	Center
(DKFZ) at	a	twelve-hour	dark/light	cycle	and	had	free	access	to	food	and	water. All
animal	experiments	were	performed	in	accordance	with	institutional	guidelines	of
the	German	Cancer	Research	Center	and	were	approved	by	the	Regierungspräsid-
ium	Karlsruhe, Germany	(G-120/12).
2.2.2 Cell	culture
Cell	lines. Human	embryonic	kidney	(HEK) 293	and	K562	(immortalised	myeloge-
nous	leukemia	line)	cells	were	grown	in	Dulbecco’s	Modiﬁed	Eagle’s	Medium	(high
glucose), supplemented	with	10%	fetal	bovine	serum, 2mM Glutamine	and	antibi-
otics	(Penicillin	and	Streptomycin, 10,000	U/ml	and	10mg/ml, resp.) at	37 °C and
5% CO2. Cells	were	routinely	passaged	by	washing	with	phosphate-buffered	saline
(PBS),	treatment	with	0.05%	Trypsin-EDTA solution	for	one	to	two	minutes	at	37°C
and	following	resuspension	in	culture	medium.
Isolation	and	culture	of	aNPCs. For	isolation	of	primary	aNPCs, mice	were	sac-
riﬁced	and	 tissue	 from	 the	 SVZ was	dissected	 into	 ice-cold	HBSS supplemented
with	1%	Penicillin-Streptomycin. Tissue	was	cut	in	small	pieces	with	a	scalpel	and
washed	three	times	with	HBSS/Pen/Strep. Subsequently	tissue	was	digested	in	PDD-
solution	at	room	temperature	 for	30	minutes. After	digestion, cells	were	washed
three	times	in	DMEM/F12	(50%	DMEM,	50%	Ham’s	F12, and	1%	L-Glutamine)	and
subsequently	triturated	using	ﬂame-polished	Pasteur	pipettes. Cells	were	afterwards
cultured	in	aNPC medium	as	neurospheres	in	25 cm2 ﬂasksat	37°C and	5% CO2.
Cells	were	passaged	once	to	twice	weekly.
Isolation	and	culture	of	GICs. Patient	derived	tumor	samples	were	dissociated	into
single	cells	and	selectively	grown	for	several	passages	as	non-adherent	spheroids	(tu-
morspheres)	in	aNPC/GIC medium. Cell	were	grown	in	25 cm2 or	75 cm2 ﬂasks	at
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37°C and	5% CO2. For	experiments	with	human	recombinant	CD95L (T4)	treat-
ment, cells	were	seeded	at	a	density	of	1x106 cells/well	 in	6-well	culture	plates.
The	cells	were	then	treated	with	10	or	40 ng/ml	human	recombinant	CD95L (T4)	at
indicated	time	points.
2.2.3 Transient	transfection	of	cultured	cells
Electroporations	of	aNPCs	and	GICs	were	performed	with	 the	Neon	Transfection
System. Prior	 to	electroporation, neurospheres	or	 tumorpsheres	were	dissociated
into	single	cells, counted, resuspended	in	R buffer	 to	a	cell	density	of	0.5-1x106
cells/100 µl, and	mixed	with	 siRNA or	plasmid	DNA.	We	used	ON-TARGETplus
SMARTpool	siRNAs	from	Thermo	Scientiﬁc. Each	pool	consists	of	four	siRNAs	tar-
geting	either	human ANKHD1 or	non-targeting	sequences. The	speciﬁc	sequences
are	shown	in	table 6. The	following	plasmids	were	used: YFP tagged	Ankhd1	plas-
mid	(YFP-Ankhd1), Flag	tagged	Ankhd1	plasmid	(Flag-Ankhd1), or	a	plasmid	with
Flag	tagged	Ankhd1	that	lacks	the	C terminal	KH domain	(Flag-Ankhd1∆C).	EYFP
plasmid	was	co	electroporated	to	assess	electroporation	efﬁciency	by	ﬂow	cytome-
try. The	siRNA was	used	at	a	concentration	of	0.5 µM,	and	plasmids	at	1 µg	/	100 µl
reaction. Electroporation	conditions	were	as	follows: 1700mA,	20ms, 1	pulse	for
tumorshperes	and	2	pulses	(30ms	width)	of	850V for	neurospheres. Electroporated
cells	were	transferred	into	6	well	plate	containing	appropriate	growth	media, and
incubated	at	37°C,	5%CO2.
Table 6: siRNA target sequences
Description	of	siRNA Sequence
human	ANKHD1	1 AGAAGGAGCAGACTTACGCACTGTGGATC
human	ANKHD1	2 AGAAGGAGCAGACTTACGCACTGTGGATC
human	ANKHD1	3 AGAAGGAGCAGACTTACGCACTGTGGATC
human	ANKHD1	4 AGAAGGAGCAGACTTACGCACTGTGGATC
mouse	ANKHD1	1 CCAAUGGGCCUGCCGAUUU
mouse	ANKHD1	2 GUCACAAUCUGUCAUAGGA
mouse	ANKHD1	3 GCACGUGGGCACCUCAUAU
mouse	ANKHD1	4 GAAUGGUAGCUCCCACUAA
non-targeting	sequence	1 UGGUUUACAUGUCGACUAA
non-targeting	sequence	2 UGGUUUACAUGUUGUGUGA
non-targeting	sequence	3 UGGUUUACAUGUUUUCUGA
non-targeting	sequence	4 UGGUUUACAUGUUUUCCUA
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2.2.4 In	utero electroporation
In	utero electroporation	was	carried	out	as	described	by	Saito [72]. Brieﬂy, timed
pregnant	C57BL/6	wild	type	mice	were	anesthetized	with	3%	isoﬂuoran	/	1.5	vol%
O2, and	anesthesia	was	maintained	with	0.5	-	1.5%	isoﬂuoran	/	1.5	vol% O2/min.
Uterine	 horns	were	 exposed	 by	midline	 laparotomy	 and	 constantly	wetted	with
warm	sterile	physiological	saline. Embryos	were	injected	with	1	-	2 µl	of	desired
DNA plasmids	and	/	or	siRNA mixed	with	0.03%	Fast	Green	with	the	help	of	heat
pulled	glass	capillaries	(bevelled	at	30º	with	an	inner	diameter	of	appr. 75-100 µm).
Five	electric	square	wave	pulses	(40V,	50ms	duration, 950ms	interval)	were	applied
with	Tweezertrodes	positioned	outside	of	the	uterine	muscle	at	approximately	45º
respective	to	the	interaural	line	of	the	embryo. Uterine	horns	were	replaced	within
the	abdomen	and	abdominal	muscle	and	skin	incisions	were	closed	with	sutures.
Mice	were	allowed	to	recover	at	37°C for	approximately	15	minutes.
If	embryos	were	used	for	analysis	24	or	48	hours	post in	utero electroporation, dams
were	sacriﬁced	and	embryos	dissected	from	uterine	horns, yolk	sac, and	amnionic
sac, followed	by	decapitation. Embryo	heads	were	transferred	into	ice	cold	PBS and
subjected	to	ﬁxation	and	cryo-protection	(see 2.2.6), or	dissection	of	cortical	tissue
(see 2.2.5). For	studying	post	natal	pups, dams	were	allowed	to	give	birth	(day	P0)
and	pups	were	 sacriﬁced	at	P2	by	decapitation, without	prior	perfusion. Heads
were	then	ﬁxed	in	4%	PFA solution	over	night	before	subjected	to	cryopreservation,
cutting	and	immuno	ﬂuorescence	staining	(see 2.2.6 and 2.2.7).
2.2.5 Dissection	of	dorsal	telencephalic	tissue	and	FACS
Heads	of	E16.5	embryos	were	placed	in	a	dish	ﬁlled	with	ice-cold	HBSS and	ﬁxed
with	needles	so	that	the	posterior	part	touched	the	bottom	of	the	well	and	the	head
was	slightly	angled	to	the	ventral	side. Skin	and	bone	tissue	was	removed	by	in-
cisions	in	a	horizontal	line	above	the	eyes, followed	by	pulling	away	of	tissue	to
the	back. Minenges	were	carefully	removed	by	taking	hold	of	it	at	the	ventrolateral
side	and	slow	pulling	towards	the	midline	from	both	sides. The	now	exposed	dorsal
telencephalic	cortices	were	dissected, discarding	the	olfactory	bulbs	and	cortical
hem. Tissues	from	litter-mates	were	collected	in	ice-cold	eNPC medium	and	sin-
gle	cell	suspension	produced	by	carefully	pipetting	up	and	down	ten	times	with	a
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200 µl	pipette. Samples	were	then	subjected	to	sorting	for	YFP positive	cells	with	a
FACSAria	II with	a	100 µm	nozzle. Cells	were	sorted	into	RNA lysis	buffer	for	later
isolation	of	total	RNA.
2.2.6 Preparation	of	cryostat	sections	from	mouse	embryo	brains
Embryo	heads	were	washed	twice	with	PBS followed	by	ﬁxation	with	4%	PFA solu-
tion	for	four	hours. PFA was	rinsed	twice	with	PBS before	incubation	in	30%	sucrose
/	PBS overnight	or	until	heads	sunk	to	the	bottom	of	the	well. Heads	were	then	shortly
put	in	OCT solution, before	placement	on	specimen	disks	and	fast	freezing	in	the
cryostat	chamber. Following	freezing, 15 µm	thick	sections	in	coronal	orientation
were	prepared	from	the	area	of	interest. Sections	were	attached	to	SuperFrost	Plus
object	slides, dried	at	room	temperature	for	approximately	30	minutes, and	stored
at	-20°C until	used	for	immuno	ﬂuorescencestaining.
2.2.7 Immunoﬂuorescence	staining	on	cryostat	cut	sections
For	immunohistochemical	analysis, cryostat	cut	sections	were	rinsed	twice	in	HBS
and	then	incubated	for	one	hour	in	blocking	solution. Sections	were	then	incubated
for	two	hours	at	room	temperature	or	over	night	at	4°C in	blocking	solution	contain-
ing	primary	antibodies	(see	table 4). Following	incubation	with	primary	antibodies,
sections	were	washed	in	blocking	solution	twice	for	ﬁve	minutes, followed	by	incu-
bation	with	the	appropriate	secondary	antibodies	(see	table 5)	and	Hoechst	33342
(1:3000)	for	one	hour	at	room	temperature. Sections	were	then	washed	twice	with
blocking	solution	and	three	times	with	PBS,	mounted	with	Fluoromount-G,	and	al-
lowed	to	dry	at	room	temperature	for	30	minutes. Stained	and	mounted	slides	were
stored	at	4°C in	 the	dark	until	 imaging. Images	were	acquired	with	a	Leica	SP5
confocal	microscope	at	the	DKFZ microscopy	core	facility	with	a	20x	objective	and
images	were	processed	with	Fiji	(ImageJ),	and	Adobe	Photoshop	software.
2.2.8 Neurosphere	cell	staining	for	ﬂow	cytometry
Neurospheres	were	harvested	and	dissociated	with	Accutase	 for	 three	minutes	at
37ºC.	Cells	were	washed	once	with	FP buffer, ﬁxed	in	4%	PFA for	ﬁve	minutes	on	ice,
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followed	by	blocking	and	permeabelization	with	SFP buffer	for	30	minutes. Cells
were	then	stained	with	primary	antibodies	for	45	minutes	on	ice, washed	twice	with
SFP buffer, and	incubated	with	secondary	antibodies	for	30	minutes	on	ice. Finally,
cells	were	washed	twice	with	FP buffer	and	resuspendend	in	200 µl	FP buffer	for	ﬂow
cytometry. Fluorescence	data	were	obtained	with	a	FACSCanto II (BD Biosciences)
and	analyzed	using	FlowJo	software.
2.2.9 In	situ hybridization
In	situ hybridization	was	performed	with	DIG labeled	probes	as	follows. ANKHD1
sense	and	antisense	riboprobes	were	DIG labeled	by in	vitrotranscription	of	cDNA
encoding	for	their	respective	sequences, using	the	DIG RNA Labeling	Kit	(SP6/T7)
from	Roche. The	riboprobe	for	ANKHD1	was	transcribed	from	a	plasmids	containing
a	sequence	covering	exons	33	and	34	(see	Fig. 7). The	sequences	used	to	clone	the
ANKHD1	fragment	used	to	generate	the	riboprobe	were 5’-CCCAAGCTTAACAGTGC-
CAGTCAGGATCG-3’ for	the	forward	primer	and 5’-CCCGGATCCTCCAATATGAGGTG-
CCCACG-3’ for	the	reverserse	primer.
Cryostat	cut	sections	from	E13.5	embryos	were	hybridized	with	digoxigenin-labeled
riboprobes	as	follows: Sections	were	permeabelized	with	PBS-Tween	for	30	minutes
at	room	temperature	and	pre-hybridized	by	incubation	in	hybridization	buffer	for
one	hour	at	68ºC.	DIG labeled	probes	were	diluted	1:500	in	hybridization	buffer
and	denatured	for	10	minutes	at	70ºC,	followed	by	quick	cool	on	ice	for	two	min-
utes. Sections	were	incubated	with	hybridization	buffer	containing	probes	i	a	wet
chamber	at	68ºC over	night. The	next	day, slides	were	washed	with	pre-warmed
(68ºC) ISH wash	 solution	 for	 three	 times	 30	minutes, followed	by	 two	 times	 30
minutes	washes	with	MABT buffer, all	shaking. Section	were	blocked	with	DIG-
blocking	reagent	for	one	hour	at	room	temperature, followed	by	anti-DIG antibody
(1:2000	in	DIG-blocking	reagent)	incubation	for	four	hours	at	room	temperature, or
at	4ºC over	night. Sections	are	then	washed	four	times	in	MABT and	ﬁve	minutes
in	staining	buffer	before	incubation	with	staining	buffer	containing	NBT (4.5µl/ml)
and	BCIP (3.5µl/ml)	in	the	dark	at	room	temperature	or	4ºC,	until	signal	becomes
visible. Sections	were	mounted	with	Eukitt	mounting	medium.
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2.2.10 EdU incorporation	assay
To	measure	proliferation	of	cells	we	used	Click-iT®	EdU incorporation	assays	from
life	technologies. EdU was	added	to	cultured	cells	at	a	ﬁnal	concentration	of	20 µM
for	 the	 indicated	 time, or	 injected	 intraperitoneally	 (1mg)	 into	dams	 for	45	min-
utes. Cells	were	then	ﬁxed	and	subjected	to	EdU detection	and	antibody	staining
according	 to	 the	manufacturer’s	 instructions. Brieﬂy, cells	were	ﬁxed	 for	15	min
with	4%	PFA and	permeabilized	for	30	minutes	at	room	temperature	in	 the	dark
using	a	saponin	based	permeabilisation	solution. Cells	were	then	stained	with	anti-
GFP antibody, treated	with	the	Click-	iT™-AlexaFluor647	azide, and	incubated	with
Hoechst	33342	to	label	DNA.	Cells	were	measured	in	a	FACSCanto II and	dot	blots
analyzed	with	FlowJo	software.
2.2.11 Dissection	of	dentate	gyrus	tissue	from	hippocampi	of	adult	mice
C57BL/6	wild	type	mice	were	anesthetized	with	an	overdose	of	Rompun	(14mg/kg
bodyweight)	and	Ketavet	(100mg/kg	bodyweight)	in	0.9%	saline	solution	and	tran-
scardially	perfused	with	20ml	of	ice	cold	HBSS.	Subsequently	the	brain	was	removed
from	the	head	and	placed	into	ice	cold	DEPC-PBS.	The	dentate	gyrus	was	dissected
from	the	brain	and	immediately	stored	in	RNAlater	at	4°C until	further	use.
2.2.12 mRNA extraction	from	cells	and	tissue
To	 isolate	RNA from	 tissues, we	used	 the	mirVana™	miRNA Extraction	Kit	with
some	modiﬁcations. Tissue	was	transferred	from	RNAlater	into	300 µl	Lysis/Binding
Buffer	and	homogenized	on	ice	with	a	30G syringe. 30 µl	microRNA homogenate
additive	was	added, the	sample	was	shortly	mixed, and	incubated	for	10	minutes
on	ice. 330 µl	of	acid-phenol:chloroform	was	added, samples	were	mixed	for	one
minute	and	centrifuged	at	13000 rpm	 for	15	minutes	at	4ºC.	The	upper	aqueous
phase	was	 transferred	into	a	 fresh	 tube	and	1.25	volumes	of	100%	ethanol	were
added. Solutions	were	then	applied	onto	spin	columns	and	centrifuged	for	15	sec-
onds	at	10000 rpm. Columns	were	washed	with	350 µl	microRNA Wash	Solution
1. DNA digestion	was	performed	by	adding	80 µl	digestion	mix	(10 µl	DNAse	and
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70 µl	RDD buffer)	onto	the	column	and	incubation	for	15	minutes	at	room	temper-
ature. Columns	were	again	washed	with	350 µl	microRNA Wash	Solution	1. Next,
columns	were	washed	twice	with	500 µl	microRNA Wash	Solution	2/3. To	remove
residual	wash	buffer, columns	were	again	centrifuged	for	one	minute	at	10000 rpm.
100 µl	DEPC-water	heated	to	95°Cwere	applied	on	the	column	followed	by	centrifu-
gation	for	one	minute	at	10000 rpm	to	elute	RNA.	In	order	to	concentrate	RNA,	10 µl
3M sodium	acetate, 2 µl	Pellet	Paint	(Novagen; Merck), and	250 µl	100%	Ethanol
was	added	and	samples	were	thoroughly	mixed. RNA was	precipitated	over	night	at
-80°C.	The	next	day, samples	were	centrifuged	for	30	minutes	at	10000 rpm	and	the
supernatant	was	discarded. Samples	were	washed	once	with	ice	cold	80%	ethanol
and	once	with	100%	ice	cold	ethanol. Pellets	were	air	dried	and	resuspended	in
20 µl	DEPC-water. RNA quality	and	quantity	was	assessed	with	a	Nanodrop	2000.
Total	mRNA from	cells	was	extracted	by	using	the	RNAeasy	Plus	Mini	Kit	from	Qi-
agen	according	 to	 the	manufacturer’s	 instructions. The	concentration	and	purity
(A260/280	ratios)	was	analyzed	with	a	Nanodrop	2000.
2.2.13 Quantitative	real	time	PCR (qRT-PCR)
Reverse	 transcription	reaction	was	performed	using	 the	Superscript III First	Strand
Synthesis	 SuperMix	 from	 Invitrogen	according	 to	 the	manufacturer’s	 instructions.
Brieﬂy, 1 µg	total	RNA in	6 µl	water	was	incubated	with	1 µl	Annealing	Buffer	and	1 µl
oligo-dTs	(50mM) for	5min	at	65°C followed	by	an	incubation	on	ice	for	one	minute.
Subsequently, 10 µl	2x	First-Strand	Reaction	Mix	and	2 µl	Superscript III/RNaseOUT
Enzyme	Mix	were	added	and	the	reaction	was	incubated	at	50°C for	50	minutes.
Enzymes	were	inactivated	for	ﬁve	minutes	at	85°C and	samples	were	immediately
chilled	on	ice.
Quantitative	real-time	PCR was	performed	with	Power	SYBR®	Green	PCR Master
Mix	in	a	96	well	plate	with	a	ABO7500	Fast	Real-Time	PCR System	Cycler	(Applied-
Biosystem). 3.52 µl	of	the	cDNA reaction	were	mixed	with	4.4 µl	of	forward	(1:20)
and	4.4 µl	of	reverse	primers	(1:20), 19.6 µl	water, and	35.04 µl	SYBR®	Green	PCR
Master	Mix. This	reaction	was	split	in	three	20 µl	aliquots	which	were	pipetted	in
a	96	well	plate	to	obtain	three	technical	replicates. Primers	used	for	qRT-PCR are
listed	in	table 7, and	cycling	conditions	were	as	follows: 2min	at	95°C,	10min	at
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95°C,	followed	by	40	cycles	of	15 s	at	95°C and	60 s	at	60°C.	Relative	levels	of	gene
expression	were	quantiﬁed, using	the	2-∆∆CT equation. Melting	curve	analysis	was
carried	out	at	the	end	of	each	run	to	check	for	non-speciﬁc	ampliﬁcation.
Table 7: Primers used for qRT-PCR
Primer	description Sequence
mouse	ANKHD1	fwd GCTCCCACTAACATTTTTCACCAG
mouse	ANKHD1	rev CCCAGAGTTCTTCCATAGTCATAG
human	ANKHD1	fwd GGAGAGTTCTCCTGTGAAGTTCTG
human	ANKHD1	rev GTCTCAGCTCCCTCCACCTT
mouse	Actin	fwd AGCGTGGCTACAGCTTCACC
mouse	Actin	rev TGTCACGCACGATTTCCCT
human	GAPDH fwd CGGTCCTGGTTGCAGGAATA
human	GAPDH rev AGAGCAAGGCAAGAAGGTCC
mouse	GAPDH fwd CCAGTGAGCTTCCCGTTCA
mouse	GAPDH rev GAACATCATCCCTGCATCCA
2.2.14 Cell	lysates
Cells	were	harvested, washed	in	chilled	PBS,	and	resuspended	in	cell	lysis	buffer.
Suspensions	were	incubated	on	a	rotating	wheel	at	4 °C for	10	to	20	minutes, ho-
mogenized	using	a	syringe	with	a	27G needle, and	then	centrifuged	at	12000 rpm,
4 °C for	5	minutes	to	remove	cell	debris. Supernatants	were	collected	(lysates)	and
stored	at	-20ºC or	used	immediately	for	Western	blotting	or	immunoprecipitation.
Protein	concentrations	were	measured	with	a	BCA assay	from	Pierce.
2.2.15 Co-immunoprecipitation
Protein	 lysates	were	prepared	 as	 described	 above	 and	used	 immediately	 for	 im-
munoprecipitation. One	tenth	to	one-twentieth	of	each	supernatant	was	saved	(‘in-
put’)	while	the	remaining	sample	was	brought	to	a	volume	of	600 µl	by	adding	lysis
buffer	(without	DTT and	protease	inhibitor). Then	3 µl	of	an	80mg/ml	bovine	serum
albumin	solution	and	and	30 µl	Protein	A/G PLUS-Agarose	beads	were	added	to-
gether	with	the	appropriate	amount	of	desired	antibody, followed	by	incubation	on
a	rotating	wheel	at	4 °C overnight. The	next	day, samples	were	washed	5	times	with
wash	buffer, beads	were	resuspended	in	30 µl	reducing	gel	loading	buffer, incubated
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at	95 °C for	5	minutes	and	either	loaded	on	SDS-polyacrylamide	gels	immediately
or	stored	at	-80 °C.
2.2.16 Sub	cellular	fractionation
Subcellular	fractionation	was	carried	out	using	the	’Subcellular	Protein	Fractionation
Kit	for	Cultured	Cells’	from	Pierce, according	to	the	manufacturer’s	instructions.
2.2.17 Western	blotting
Equal	amounts	of	protein	samples	(25–50 µg)	were	fractionated	on	12%	SDS-poly-
acrylamide	gels	or	pre-cast	4-20%	gradient	gels	at	180V for	approximately	45	min-
utes. Proteins	were	the	transferred	to	nitrocellulose	membranes	(Biorad	Trans-Blot®,
0.45 µm). The	gel	and	the	membrane	were	placed	between	sheets	of	absorbent	pa-
per	and	immersed	in	transfer	buffer	in	a	semi-dry	blotting	chamber. Blotting	was
performed	at	10V and	150mA for	1	hour. Following	transfer, non-speciﬁc	bind-
ing	sites	on	the	nitrocellulose	membrane	were	blocked	by	incubation	with	5%	skim
milk	powder	in	PBS-Tween	(milk/PBST) for	one	hour. Membranes	were	incubated
with	primary	antibodies	(see	table 4)	diluted	in	milk/PBST overnight	at	4°C.	The	next
day, membranes	were	washed	with	with	milk/PBST twice	for	10	minutes, followed
by	incubation	with	HRP-conjugated	secondary	antibodies	(see	table 5)	in	milk/PBST
for	one	hour	at	room	temperature. Following	several	thorough	washed	with	PBST,
the	HRP signal	was	detected	by	incubation	with	Enhanced	Chemi	Luminescence	so-
lution	according	to	the	manufacturer’s	instructions	and	exposure	to	Kodak	X-Omat
ﬁlms. For	removal	of	antibody	complexes	from	nitrocellulose	membranes	for	reprob-
ing	with	different	antibodies, membranes	were	incubated	with	stripping	buffer	for
30	minutes	at	55°C.	After	thorough	washing	with	PBST,	membranes	were	reprobed
as	described	above.
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3 Results
ANKHD1	and	its	homolog	MASK in	Drosophila	were	shown	to	be	important	reg-
ulators	of	cell	proliferation	and	differentiation. Published	observations	 regarding
ANKHD1	expression	as	well	as	unpublished	observations	in	our	lab, led	us	to	hy-
pothesize	that	ANKHD1	might	be	involved	in	regulating	NPC functions. First, we
wanted	to	characterize	ANKHD1	expression	in	the	developing	mouse	brain	and	in
adult	NPCs. Later	test	its	function...
3.1 ANKHD1	expression	in	the	murine	brain
Expression	of	ANKHD1	in	the	developing	mouse	brain	has	not	been	investigated
yet. In	adult	brain, the	only	evidence	comes	from	a	paper	published	by	Poulin	et al.
[65] where, alongside	various	other	tissues, brain	lysate	was	used	in	a	quantitative
real	time	PCR experiment	and	ANKHD1	was	detected	therein. However, ANKHD1
protein	expression	in	the	adult	brain	has	not	been	described	yet. We	used	quanti-
tative	real	time	PCR,	Western	blotting	and in	situ hybridization	to	test	for	ANKHD1
expression	in	the	developing	and	adult	mouse	brain.
First, ANKHD1	mRNA levels	in	dissected	dorsal	telencephalic	cortices	from	various
embryonic	stages	were	analyzed	by	quantitative	real	 time	PCR.	We	used	primers
that	speciﬁcally	detect	 the	 full	 length	canonical	 isoform	of	ANKHD1	and	do	not
bind	to	ANKHD1-BP3, a	gene-fusion	product	reported	by	Poulin	et al. [65]. This
was	achieved	by	placing	the	primers	at	the	N-terminus	of	the	protein5, and	includ-
ing	exon	34	(the	last	exon)	which	is	unique	to	ANKHD1	(Figure 6A).	As	shown	in
Figure 6B,	ANKHD1	could	be	detected	as	early	as	E12.5	and	in	all	following	embry-
onic	stages	tested	(E13.5	-	E17.5). Levels	tended	to	increase	at	later	stages	compared
to	E12.5. Moreover, ANKHD1	was	also	found	to	be	expressed	in	the	developing
ventral	forebrain, i.e. the	ganglionic	eminences	at	robust	levels	(Figure 6C).
We	further	investigated	mRNA expression	in	the	developing	forebrain	by	performing
in	situ hybridization	on	saggital	cryomicrotome	cut	sections	of	selected	embryonic
stages. Again, in	situ RNA probes	were	designed	to	speciﬁcally	detect	the	full	length
canonical	isoform. A broad	expression	of	ANKHD1	in	the	neocortex	and	ganglionic
5All	reported	isoforms	are	truncated	on	the	N terminal	side, and	thus	will	not	be	recognized	by	the
designed	primers
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Figure 6: ANKHD1 mRNA is expressed throughout neocortical development. A | Schematic repre-
sentation of the ANKHD1 gene structure in its genomic locus and positioning of primers for quantita-
tive real time PCR. The last three exons of ANKHD1 (32-34), the intermediate exon 0, and the ﬁrst two
exons of the downstream gene 4E-BP3 are shown on top. Beneath, mRNA transcripts of ANKHD1
and the fusion protein ANKHD1-BP3 are displayed. Red arrows indicate position of primers used
for detection of ANKHD1. B | mRNA was prepared from dorsal telencephalic cortices from indicated
embryonic stages (E12.5 - E17.5) and tested for ANKHD1 expression with above mentioned primers.
Expression values are normalized to the E12.5 data point. C | ANKHD1 mRNA expression in dorsal
telencephalic cortices and ganglionic eminences from E14.5 embryos was compared by quantitative
real time PCR. Expression values are normalized to one replicate from the E12.5 data point.
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eminences	was	evident	at	E13.5	(Figure 7A).	In	the	neocortex, strong	expression	was
present	in	the	ventricular	and	subventricular	zones	(Figure 7B).
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Figure 7: ANKHD1 mRNA expression assessed by in
situ hybridization. A | Schematic illustration of
RNA probe position for ANKHD1 detection by in situ hybridization. The probe was designed to span
over two exons and include exon 34, which is unique to ANKHD1 (compare with Figure 6). B | 15
µm saggital cryo-cut sections of E13.5. heads were prepared and subjected to in situ hybridization.
Scale bar= 20 µm. C | Higher magniﬁcation of neocortex from images shown in B. Scale bar= 100 µm.
Ncx= neocortex, GE= ganglionic eminences, D= dorsal, V= ventral, A= anterior, P= posterior.
To	test	wether	ANKHD1	mRNA is	also	translated	and	the	protein	expressed, we	per-
formed	Western	blot	analysis	of	various	embryonic	and	adult	mouse	brain	samples.
At	E12.5, only	very	low	levels	of	ANKHD1	protein	could	be	detected. At	all	later
stages	tested	(until	E17.5), the	protein	was	readily	detected. Moreover, in	short	term
cultured	primary	adult	NPCs, strong	ANKHD1	expression	was	observed.
Adult	NPC function	decreases	with	aging. To	further	investigate	the	expression	pat-
tern	of	ANKHD1	during	adulthood, we	measured	mRNA levels	of	ANKHD1	in	den-
tate	gyri	 form	mice	of	different	age. As	seen	in	Figure 9, ANKHD1	was	detected
throughout	all	age	time	points	collected, including	in	15	months	old	mice, and	lev-
els	did	not	seem	to	vary	to	any	signiﬁcant	extent	throughout	life.
Due	to	the	lack	of	suitable	antibodies, no	immuno	ﬂuorescence	stainings	were	per-
formed	on	mouse	brain	sections. Together, these	data	suggest	that	ANKHD1	is	ex-
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Figure 8: ANKHD1 protein is expressed in embryonic and adult neural progenitor cells. Protein
lysates were prepared from either dorsal telencephalic cortices at the indicated embryonic day (E12.5-
E17.5), or from short term cultured adult neural progenitor cells. Western blots were tested with
antibodies against ANKHD1 (upper row) or GAPDH (lower row).
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Figure 9: ANKHD1 is expressed in aNPCs throughout life. Total RNA was isolated from dissected
dentate gyri from Bl6 mice of different age (3 to 15 months). Samples were subjected to quantita-
tive real-time PCR with ANKHD1 primers. Data were normalized to beta-Actin expression and are
displayed as fold change to the ﬁrst data point (3 month time point). n= at least two for each age.
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pressed	on	RNA and	protein	level	throughout	neocortical	development	and	remains
present	in	adult	NPCs	at	high	levels.
3.2 ANKHD1	regulates	cell	cycle	progression	in	adult	NPCs
Given	the	expression	of	ANKHD1	in	adult	NPCs	and	its	function	in	other	progenitor
cells	[84], we	hypothesized	that	it	may	be	involved	in	aNPC proliferation	and	differ-
entiation. We	ﬁrst	sought	to	investigate	the	effect	of	ANKHD1	on	NPC proliferation.
Because	no	knockout	mice	or	cells	are	available, we	used	siRNA directed	against
ANKHD1	to	knock	it	down	through	transient	transfection	of	cells. Adult	NPCs	were
isolated	from	Bl6	mice	and	cultured	as	neurospheres	in	serum	free	media. 48	hours
after	knockdown	of	ANKHD1	with	siRNA,	cells	were	treated	with	EdU for	45	min-
utes. Subsequently	the	samples	were	subjected	to	immunoﬂuorescence	staining	for
ﬂow	cytometry	with	anti	GFP antibody	(detection	of	transfected	cells)	and	detection
of	EdU via	a	copper	catalyzed	covalent	reaction	between	an	ﬂuorophor	coupled
azide	and	the	ethynyl	moiety	of	EdU (Figure 10). Interestingly, the	number	of	cells
that	incorporated	EdU was	increased	by	approximately	50%	when	ANKHD1	was
knocked	down	compared	to	cells	transfected	with	non-targeting	siRNA (Figure 10B-
C),	indicating	that	ANKHD1	might	be	involved	in	negative	regulation	of	cell	prolif-
eration.
Next, we	tested	if	knockdown	of	ANKHD1	in	cultured	aNPCs	inhibited	differentia-
tion	in	addition	to	increasing	proliferation. When	grown	under	”stem	cell”	condi-
tions	as	neurospheres, only	very	few	cells	will	be	able	to	differentiate. However, af-
ter	withdrawal	of	EGF and	FGF growth	factors, cells	differentiate	and	express	markers
of	post	mitotic	neurons	(such	as -III-tubulin). Cultured	NPCs	were	transfected	with
either	ANKHD1	or	non-targeting	siRNA and	grown	under	differentiating	conditions
for	six	days. As	seen	in	Figure 11, the	amount	of -III-tubulin	positive	cells	amongst
all	transfected	cells	was	decreased	when	ANKHD1	was	knocked	down. Conversely,
the	proportion	of -III-tubulin	positive	cells	increased	when	human	ANKHD1	was
overexpressed. Human	 full	 length	ANKHD1	was	used	 for	overexpression	exper-
iments	because	mouse	ANKHD1	has	not	been	cloned	by	us	or	others, including
commercial	providers, yet. Due	to	the	high	similarity	between	human	and	mouse
ANKHD1	we	hypothesized	that	those	two	proteins	might	be	interchangeable	(see
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1.5 and 3.3.4). However, only	few	cells	could	be	measured	because	electropora-
tion	was	very	inefﬁcient	(due	to	the	large	size	of	full-length	ANKHD1). Together,
this	data	suggest	that	knockdown	of	ANKHD1	can	promote	proliferation	of	aNPCs
in	vitro and	inhibit	their	differentiation.
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Figure 10: ANKHD1 knockdown promotes proliferation of aNPCs in
vitro. Low passage aNPCs
were electroporated with a YFP plasmid and siRNA targeted against ANKHD1 (KD) or non-targeting
control siRNA (NT). 48 hours later cells were treated with 10 µM EdU for 30 (B) or 45 (C) minutes
followed by immuno ﬂuorescence staining and EdU detection. A | Representative ﬂow cytometry dot
plots and gating strategy shown for a control sample. First the living cell population was selected and
doublets excluded, followed by gating on YFP positive cells and subsequently EdU positive cells.
Number of EdU positive cells amongst all YFP positive cells was measured. B | Percentage of EdU+
cells amongst all YFP+ cells after 30 minutes of EdU treatment. C | Percentage of EdU+ cells amongst
all YFP+ cells after 45 minutes of EdU treatment. D | Relative increase in number of of EdU+ cells of
B and C combined. n=4 (2 each for 30’ and 45’ treatment), **p<0.05, unpaired Student’s t-test.
3.3 ANKHD1	regulates	proliferation	during	cortical	development
We	observed	ANKHD1	expression	in	the	developing	neocortex	and	other	prolifer-
ating	regions	of	the	brain	(see	Figures 6-8). The	role	of	ANKHD1	in	the	developing
brain	has	not	been	studied	yet. In	 fact, it	has	not	been	studied	 in	any	other	 tis-
sue	during	mammalian	development	 so	 far. Knockout	mice, that	would	provide
great	insight	into	the	role	of	ANKHD1	during	development, are	not	available	yet.
The	drosophila	homolog	of	ANKHD1, MASK,	has	been	reported	to	be	 important
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Figure 11: ANKHD1 promotes diﬀerentiation of aNPCs in
vitro. Low passage aNPCs were elec-
troporated with a YFP plasmid and siRNA targeted against ANKHD1 (knockdown) or non-targeting
control siRNA (control), or with pCAG-YFP-ANKHD1. Six days later cells were stained with GFP and
-III-tubulin antibodies and analyzed by ﬂow cytometry.
for	photoreceptor	progenitor	proliferation	and	differentiation	during	development.
Moreover	some	MASK mutants	are	embryonic	lethal	[84]. Based	on	our	expression
data	and	 functional	 roles	of	ANKHD1	in	progenitor	cells	of	other	organisms, we
hypothesized	that	it	might	play	an	important	role	during	murine	brain	development.
Thus, we	next	set	out	to	investigate	the	role	of	ANKHD1	in	murine	embryonic	neural
progenitor	cells	(eNPCs).
3.3.1 Knockdown	of	ANKHD1	increases	proliferation	of	eNPCs
Despite	the	lack	of	knockout	mice, eNPC function	can	be	studied in	vivo by	uti-
lizing	the in	utero electroporation	technique	to	speciﬁcally	target	radial	glia	cells:
Uterine	horns	of	anesthetized	dams	are	exposed, followed	by	DNA or	RNA injec-
tion	into	the	lateral	ventricle	and	electroporation	with	forceps	type	electrodes	(see
methods	for	details). We	knocked	down	ANKHD1	in	radial	glia	of	E13.5	and	E14.5
mice	and	measured	EdU incorporation	into	eNPCs	48	hours	later. Illustration	of	the
experimental	layout	and	representative	dot	plots	from	ﬂow	cytometry	analysis	are
shown	in	Figure 12A and	B,	respectively. Strikingly, the	number	of	progenitor	cells
that	incorporated	EdU was	markedly	increased	from	5.6%	±	0.2	to	12.4%	±	0.45
(E13.5, Figure 12C) and	5.8%	±	0.7	to	9.7%	±	0.9	(E14.5, Figure 12C) in	ANKHD1
knockdown	samples. Note	that	the	rather	low	number	of	cells	incorporating	EdU is
due	to	the	fact	that	YFP positive	post	mitotic	cells	(i.e. immature	neurons	generated
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from	labeled	progenitors)	were	not	excluded	from	the	analysis. These	cells	account
for	approximately	55%	of	all	labeled	cells. Together	with	a	rather	short	EdU pulse
time	of	three	hours	the	measured	numbers	are	reasonable	and	comparable	to	data
obtained	 in	other	publications. Due	to	 lack	of	suitable	antibodies	we	conﬁrmed
knockdown	of	ANKHD1	in	electroporated	brains	by	qRT-PCR.	Tissue	around	elec-
troporated	area	was	dissected	48	hours	post	IUE and	sorted	 for	YFP positive	cells
(3–4	embryos	were	pooled	 for	each	sample). Total	RNA was	 isolated	and	 tested
with	 primers	 recognizing	ANKHD1. Knockdown	of	ANKHD1	was	 at	 least	 40	 –
60%. Primes	used	showed	some	degree	of	self-annealing	and	thus	actual	ANKHD1
knockdown	probably	was	even	more	efﬁcient.
3.3.2 The	apical	and	basal	progenitor	pool	is	expanded	after	ANKHD1
knockdown
The	increased	EdU incorporation	could	be	a	consequence	of	altered	radial	glia	cell
behavior, changes	in	basal	progenitor	proliferation	and	/	or	differentiation, or	both.
To	gain	 further	 insight	 into	 the	expanding	progenitor	pool, we	next	performed in
utero electroporation	of	E14.5	embryos	followed	by	immuno	ﬂuorescencestaining
of	 sections	 for	 the	 basal	 progenitor	marker	Tbr2	 and	 the	 neuronal	marker	 Satb2
(Figure 13A).	By	using	marker	expression	and	location	information	(see	Figure 13 E),
radial	glia, basal	progenitors, and	post-mitotic	neurons	can	be	distinguished. In-
terestingly, in	ANKHD1	knockdown	 samples	 the	number	of	 radial	 glia	 cells	was
increased	from	12.49	±	0.83	to	17.17	±	3.05	(Fig. 13B) and	the	number	of	basal
progenitor	cells	was	increased	from	30.56%	±	1.03	to	39.14%	±	2.25	(Fig. 13C).
The	number	neurons	generated	from	transfected	radial	glia	cells	during	the	observa-
tion	period	decreased	from	56.95%	±	0.36	to	43.70%	±	3.68	(Fig. 13D).	This	data
suggest	that	ANKHD1	is	required	for	normal	progenitor	proliferation	and	differenti-
ation.
3.3.3 Overexpression	of	human	ANKHD1	promotes	differentiation	into	neurons
We	hypothesized	 that	overexpression	ANKHD1	would	 increase	differentiation	of
NPCs. To	test	this	hypothesis	we	overexpressed	human	ANKHD1	in	eNPCs. The
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Figure 12: ANKHD1 knockdown promotes eNPC proliferation in
vivo. A | Schematic illustration of
in utero electroporation and subsequent analysis. B | Representative ﬂow cytometry dot plots and
gating strategy of a control (upper row) and ANKHD1 knockdown (lower row) sample. First the living
cell population was selected and doublets excluded, followed by gating on YFP positive cells and
subsequently EdU positive cells. Number of EdU positive cells amongst all YFP positive cells was
measured. C | E13.5 embryos were electroporated with either pCAG-YFP and non-targeting siRNA
(CO) or pCAG-YFP and siRNA against ANKHD1 (KD). Dams were injected i.p. with 1 mg EdU 45
hours later and sacriﬁced 3 hours after EdU injections. n=4 for CO and 2 for KD from two litters. Data
are presented as mean and individual values, ***p<0.001, unpaired Student’s t-test. D | Same as in
C, but here E14.5 embryos were electroporated. n=5 for CO and 6 for KD, from two litters. Data
are presented as mean and individual values, **p<0.01, unpaired Student’s t-test. E | Knockdown of
ANKHD1 was conﬁrmed by qRT-PCR. Embryos were electroporated as in C and D. 48 hours later
tissue around electroporated area was isolated and sorted for YFP positive cells. Total RNA was
isolated from these cells and tested for ANKHD1 expression. n=2 (3–4 embryos pooled per sample).
Expression values are normalized to controls.
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Figure 13: ANKHD1 knockdown promotes apical and basal progenitor proliferation in
vivo. A |
Representative images of E16.5 neocortex sections 48 hours after in utero electroporation. Control
(upper panels) and ANKHD1 knockdown samples (lower panels) were stained for YFP (middle-left
panels), and Tbr2 (middle-right panels). Merged images are shown in panels on the right and nuclei
were counter-stained with Hoechst (left panels). VZ= ventricular zone, SVZ=subventricular zone,
IZ=intermediate zone, CP=cortical plate, V=ventral, M=medial. Scale bar=50 µm. B-D | Percentage
of radial glia cells (B), basal progenitor cells (C), and neurons (D) amongst all transfected cells in
embryos electroporated with non-targeting siRNA (CO) or siRNA against ANKHD1 (KD). n=5 embryos
for CO and n=6 embryos for KD from four different litters; total number of cells counted: n=1007 for
CO and n=1010 for KD. **p<0.01, ***p<0.001, two-way ANOVA. E | Discrimination of RG, BPs, and
neurons is based on marker expression and location.
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human	and	mouse	homologs	of	ANKHD1	are	vey	 similar. Both	 the	ankyrin	do-
mains	and	the	KH domain	are	highly	conserved	in	sequence	and	position	(see 1.5
for	details). We	have	obtained	a	human	cDNA clone	from	genecopedia	and	sub-
cloned	it	to	suitable	expression	vectors	in	order	to	study	overexpression	phenotypes
in	NPCs.
We	overexpressed	human	ANKHD1	in	the	neocortex	of	E14.5	embryos	via in	utero
electroporation	and	compared	phenotypes	48	hours	later	(Fig 14). Interestingly, ec-
topic	expression	of	ANKHD1	led	to	increased	differentiation	into	neurons	compared
to	controls. More	cells	with	immature	neuron	morphology	were	located	in	the	inter-
mediate	zone	and	cortical	plate	compared	to	controls, and	fewer	cells	were	found	in
the	VZ/SVZ (compare	upper	and	middle	row	in	Fig. 14). Moreover, when	we	overex-
pressed	a	truncated	form	of	ANKHD1	that	is	missing	the	KH domain	(ANKHD1-∆C),
differentiation	to	neurons	was	reverted	to	normal	levels	(Fig. 14, last	row).
3.3.4 Overexpression	of	human	ANKHD1	rescues	knockdown	phenotype
Overexpression	of	 human	ANKHD1	 led	 to	 converse	 effects	 compared	 to	 knock-
down	conditions	(compare	Fig. 13 and	Fig. 14). We	thus	wondered	if	we	could	res-
cue	the	ANKHD1	knockdown	phenotype	by	simultaneously	overexpressing	human
ANKHD1. We	co-electroporated	mouse	ANKHD1	siRNA and	a	human	ANKHD1
overexpression	plasmid	in	E14.5	embryos	and	analyzed	them	48	hours	later	(Fig. 15).
Co-electroporation	of	human	ANKHD1	could	revert	progenitor	populations	close	to
control	levels	and	partially	rescue	differentiation	into	neurons.
3.4 ANKHD1	sub-cellular	localization	and	interaction	partners
3.4.1 ANKHD1	can	localize	to	the	nucleus	in	NPCs
The	mechanisms	by	which	ANKHD1	functions	are	largely	unknown. ANKHD1	was
shown	to	interact	with	the	Hippo	pathway	component	YAP in	various	cell	lines	[74,
81], and	to	be	partly	required	for	YAP activity. However, if	they	shuttle	to	the	nucleus
together	and	if	ANKHD1	has	a	function	in	the	nucleus	remains	controversial.
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Figure 14: ANKHD1 overexpression promotes diﬀerentiation in
 vivo. Representative images of
E16.5 neocortex sections 48 hours after in utero electroporation. Control (YFP, upper row), ANKHD1
overexpression (YFP-hANKHD1, middle row) and c-terminal truncated ANKHD1 overexpression
(Flag-ANKHD1-∆C, lower row) were stained for GFP or Flag (middle-left panels) and -III-tubulin
(middle-right panels). Merged images are shown in panels on the right; nuclei were counter stained
with Hoechst (left panels). VZ= ventricular zone, SVZ=subventricular zone, IZ=intermediate zone,
CP=cortical plate, V=ventral, L=lateral, M=medial. Scale bar=50 µm.
We	ﬁrst	analyzed	the	mouse	ANKHD1	for	a	nuclear	localization	and	nuclear	ex-
port	signal	(NLS and	NES,	resp.).Using	the	protein	predict	platform	[71], a	stretch
from	position	1458	to	1477	was	identiﬁed	as	potential	NLS (Figure 16A).	The	 se-
quence	is KREKRKEKRKKKKEEQKRK,	and	it	is	highly	conserved	across	species	(100%
in	those	tested, Figure 16B).	This	sequence	is	also	100%	identical	in	the	only	paralog
of	ANKHD1, Ankrd17—which	has	been	shown	to	locate	to	the	nucleus. Further-
more, we	performed	nuclear	fractionation	of	aNPCs	lysates	and	tested	for	ANKHD1
abundance	within	them. The	majority	of	the	protein	is	localized	in	the	cytoplasm,
however, ANKHD1	can	be	clearly	detected	in	the	nucleus	as	well. Due	to	lack	of
suitable	antibodies, we	were	unable	to	test	for	localization	of	endogenous	ANKHD1
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Figure 15: Overexpression of human ANKHD1 rescues knockdown phenotype. A | Representative
images of E16.5 coronal neocortex sections 48 hours after in utero electroporation. Control (upper
panels) and ANKHD1 knockdown samples (lower panels) were stained for YFP (middle-left panel), and
Tbr2 (middle-right panel). Merged images are shown in panels on the right and nuclei were counter
stained with Hoechst (left panels). VZ= ventricular zone, SVZ=subventricular zone, IZ=intermediate
zone, CP=cortical plate, D=dorsal, M=medial. Scale bar=50 µm. B-D | Percentage of radial glia cells
(B), basal progenitor cells (C), and neurons (D) amongst all transfected cells in samples electroporated
with non-targeting siRNA (CO), siRNA against ANKHD1 (KD), or siRNA against ANKHD1 together with
pCAG-YFP-hANKHD1 (RE). n=2 embryos from two different litters; total number of cells counted:
n=482 for CO, n=621 for KD, and n=481 for RE, *p<0.05, two-way ANOVA.
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on	tissue	sections. Notably, when	we	overexpressed	YFP tagged	ANKHD1	in	eNPCs
in	vivo, we	observed	it	mainly	in	the	cytoplasm, but	also	in	the	nucleus, similar	to
the	fractionation	experiments. Both	Sansores-Garcia	et al. [74] and	Sidor	et al. [81]
showed	that	ANKHD1	can	interact	with	YAP,	and	Sidor	et al. [81] suggested	that
ANKHD1	and	YAP might	translocated	to	the	nucleus	together. While	YAP expres-
sion	in	the	developing	brain	is	rather	low, the	other	known	effector	of	the	Hippo
pathway	in	mammals, TAZ (or	WWRP1)	is	highly	expressed	in	the	ventricular	and
sub	ventricular	zones	during	neocortical	development. We	ﬁrst	tested	if	ANKHD1
interacts	with	YAP in	eNPC by	isolating	E13.5. dorsal	telencephalic	cortices	and
performing	co-immunoprecipitation	experiments. So	far, we	were	not	able	to	de-
tect	an	interaction	of	YAP and	ANKHD1	in	eNPCs. A possible	interaction	with	TAZ
has	not	been	tested	yet. Together, our	observations	suggest	that	ANKHD1	can	lo-
calize	to	the	nucleus	in	eNPCs, although	its	predominant	location	seems	to	be	in
the	cytoplasm. Moreover, if	ANKHD1	interacts	with	the	Hippo	pathway	in	NPCs	as
well	remains	elusive.
3.4.2 ANKHD1	does	not	interact	with	SHP2	to	promote	NPC proliferation
It	was	previously	reported	that	ANKHD1	can	interact	with	the	tyrosine-protein	phos-
phatase	SHP2	(PTPN11)	in	the	human	leukemia	cell	line	K562. SHP2	is	known	to
be	important	during	brain	development, controlling	the	switch	from	neurogenesis
to	gliogenesis	and	promoting	proliferation	of	NPCs. Hence, we	hypothesized	that
ANKHD1	might	interact	with	SHP2	in	embryonic	NPCs	as	well, and	at	least	partially
function	via	the	SHP2	signaling	pathways. We	performed	co-immunoprecipitation
with	both	ANKHD1	and	SHP2	antibodies	to	test	their	interaction	in	freshly	isolated
dorsal	telenchephalic	cortices	from	E13.5	embryos. As	shown	in	Figure 17, we	could
not	observe	interaction	between	the	two	proteins, independent	of	which	antibody
was	used	to	perform	the	immunoprecipitation.6
6N.B.: We	were	unable	to	reproduce	interaction	of	ANKHD1	and	SHP2	in	K562	cells	(data	not
shown).
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Rattus norvegicus    1405 LEKSREESRKQALAAKREKRKEKRKKKKEEQKRKQE-DEENKPKVNSEQPEGEDEE 1483
Gallus gallus        1399 LEKSREESRKQALAAKREKRKEKRKKKKEEQKRKQEEDEENKPKETLELHEDDDEE 1478
Mesocricetus auratus 1398 LEKSREESRKQALAAKREKRKEKRKKKKEEQKRKQE-DEENKPKENSEQPEGEDEE 1476
Sus scrofa           1408 LEKSREESRKQALAAKREKRKEKRKKKKEEQKRKQEEDEENKPKENSELPEDEDEE 1487
Bos taurus           1408 LEKSREESRKQALAAKREKRKEKRKKKKEEQKRKQEEDEENKPKENSELPEDEDEE 1487
Canis familiaris     1408 LEKSREESRKQALAAKREKRKEKRKKKKEEQKRKQEEDEENKPKENSELPEDEDEE 1487
Danio rerio          1407 LEKSREESKKQALAAKREKRKEKRKKKKEEQKRKLE-EEEAKVKEVSFEMLDQKED 1485
Equus caballus       1408 LEKSREESRKQALAAKREKRKEKRKKKKEEQKRKQEEDEENKPKENSELPEDEDEE 1487
Pan paniscus         1411 LEKSREESRKQALAAKREKRKEKRKKKKEEQKRKQEEDEENKPKENLELPEDEDEE 1490
Xenopus tropicalis   1375 LEKSREESRKQALAAKREKRKEKRKKKKEEQKKKLGDDEDSKILEIFDL---QDEE 1451
Macaca fascicularis  1428 LEKSREESRKQALAAKREKRKEKRKKKKEEQKRKQEEDEENKPKENSELPEDEDEE 1507
Macaca mulatta       1377 LEKSREESRKQALAAKREKRKEKRKKKKEEQKRKQEEDEENKPKENSELPEDEDEE 1456
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Figure 16: ANKHD1 contains a putative NLS and can localize to the nucleus. A | Putative nuclear
localization signal (NLS) in human ANKHD1. NLS highlighted as identiﬁed by prediction with preditpro-
tein.org [71] and ELM [20]. B | Protein sequence alignment of ANKHD1 from various species. Aligned
with COBALT. Accession numbers of shown species: Homo sapiens (NP_060217.1), Mus musculus
(NP_780584.2), Rattus norvegicus (NP_001190982.1), Gallus gallus (NP_001191026.1), Mesocrice-
tus auratus (XP_005069288.1), Sus scrofa (NP_001190196.1), Bos taurus (XP_005209554.1), Ca-
nis familiaris (NP_001191024.1), Danio rerio (NP_001186697.1), Equus caballus (NP_001191034.1),
Pan paniscus (XP_003829227.1), Xenopus tropicalis (NP_001191021.1), Macaca fascicularis
(XP_005558028.1), Macaca mulatta (XP_002804593.1). C | Alignment of human ANKHD1 and
its paralog Ankrd17 with Clustal Omega, accession numbers: ANKHD1, see above, Ankrd17:
NP_115593.3. D | Western Blot of sub-cellular fractions of aNPCs. C = cytoplasmic extract, M =
membrane extract, N = nuclear extract, N+ = chromatin-bound extract, P = pellet extract. E | pCAG-
YFP-ANKHD1 was overexpressed via in utero electroporation in E14.5 neocortex. Cryomicrotome
sections were prepared 48 hours later and stained with GFP antibody.
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Figure 17: ANKHD1 does not interact with SHP2. Dorsal cortices of E13.5 embryos were dissected,
followed by cell lysis and immunoprecipitation with either ANKHD1 antibody (lane 4), SHP2 antibody
(lane 3), or an isotope control antibody (lane 2). 5% of total cell lysate were kept as input sample (lane
1). *heavy chain IgG from antibodies used for immunoprecipitation.
3.5 Role	of	ANKHD1	in	glioma	initiating	cells
Gliobastoma	multiforme	is	likely	to	origin	from	neural	progenitor	cells	in	the	brain
(see 1.4.2). Based	on	our	observations	regarding	ANKHD1	effects	on	proliferation	in
neural	progenitor	cells, we	wanted	to	investigate	ANKHD1	levels	in	various	glioma
initiating	cell	(GIC) cultures, and	elucidate	if	ANKHD1	is	also	involved	in	prolifera-
tion	control	of	these	cells.
3.5.1 ANKHD1	is	expressed	in	glioma	initiating	cells
First, we	 tested	ANKHD1	expression	 in	 various	GIC cultures	 (we	 received	GBM
samples	from	two	different	hospitals	and	denote	them	GBM or	NMA,	depending	on
their	source, see 2.2.2 for	details)	by	Western	blotting. ANKHD1	was	detected	in	all
cultures	in	varying	amounts. All	samples	had	a	stronger	expression	than	a	human
brain	parenchyma	control	lysate.7 ANKHD1	has	various	shorter	isoforms	(see	in-
troduction). Five	main	bands	were	detected	in	all	GIC samples	with	the	polyclonal
ANKHD1	antibody	used, and	all	ﬁve	of	these	bands	were	affected	by	knockdown
with	siRNA designed	against	ANKHD1(see	Figure 23). The	ratio	of	the	canonical
isoform	to	smaller	products	did	vary	from	sample	to	sample	but	was	usually	stable
for	a	given	GIC culture	over	time. Notably, very	little	full	length	ANKHD1	was	de-
tected	in	GBM 14	(not	shown)	and	39	(see	Figure 18, lane	7). One	sample, GBM 29,
displayed	two	bands	larger	than	the	full	length	protein. These	bands	are	of	unknown
7A more	suitable	control	 to	compare	expression	levels	would	be	human	adult	neural	stem	cells
which, however, were	not	available
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identity; they	might, however, represent	the	ANKHD1-BP3	fusion	protein	described
by	Poulin	et al. [65]. These	data	suggest	 that	ANKHD1	is	either	generally	highly
expressed	in	GBM or	enriched	in	GICs.
WB: Ankhd1
WB: Actin
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Figure 18: ANKHD1 expression in GBM Various GIC cultures were tested for ANKHD1 expression.
Total lysates were prepared and tested with antibodies against ANKHD1 (upper panels) or beta-Actin
(lower panels). All ﬁve bands in upper levels detect ANKHD1: the largest is representing the canonical
isoform, while the others are other isoforms or break down products. The very large band in GBM
29 is of unknown origin. hBPL= human brain parenchyma lysate.
3.5.2 Overexpression	of	ANKHD1	increases	proliferation	of	cultured	glioma
initiating	cells
Next, we	tested	if	knockdown	or	overexpression	of	ANKHD1	had	similar	effect	on
proliferation	of	GICs	as	observed	for	murine	NPCs. We	have	chosen	two	different
GIC cultures	(GBM 13	and	30)	for	following	experiments. Cells	were	transfected	by
electroporation, either	with	siRNA targeting	human	ANKHD1	together	with	a	pCAG-
YFP plasmid, non-targeting	siRNA with	pCAG-YFP,	or	a	YFP-ANKHD1	plasmid	un-
der	the	control	of	a	CAG promoter. Knockdown	and	overexpression	were	checked
by	quantitative	real-time	PCR (see	Figure 20B and	D) and	also	conﬁrmed	by	Western
blotting	(see	Figure 23 for	an	example). To	determine	the	effect	of	ANKHD1	knock-
down	or	overexpression	on	GIC proliferation, EdU incorporation	was	measured	by
ﬂow	cytometry	72	hours	after	electroporation. Flow	cytometry	dot	plots	and	gating
strategies	for	representative	samples	are	shown	in	Figure 19. Interestingly, other	then
in	murine	NPCs, knockdown	of	ANKHD1	did	not	have	an	effect	on	GIC prolifera-
tion	in	any	of	the	two	cultures	tested	(Figure 20A and	C;	GBM13: control	=	10.90%
±	0.70, knockdown	=	13.35%	±	1.55; GBM30: control	=	6.72%±	2.02, knockdown
=	9.68%	±	0.63). However, compared	to	control	samples, overexpression	markedly
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increased	EdU incorporation	in	both	GBM 13	(10.90%	±	0.70	vs.	33.15%	±	0.45)
and	GBM 30	(6.72%	±	2.02	vs.	27.55%	±	0.15). These	results	suggest	that	ANKHD1
promotes	cell	proliferation	in	GICs.
3.5.3 ANKHD1	regulates	p21	levels	in	glioma	initiating	cells
It	was	previously	reported	that	ANKHD1	can	promote	proliferation	of	multiple	my-
eloma	cells	and	regulate	expression	levels	of	the	cyclin	dependent	kinase	inhibitor
p21. To	test	if	ANKHD1	has	an	inﬂuence	on	p21	expression	levels	in	GICs, we	per-
formed	knockdown	and	overexpression	experiments	in	GBM13	cells	and	examined
p21	levels	via	Western	blotting. Compared	to	cells	transfected	with	non-targeting
siRNA,	knockdown	of	ANKHD1	led	to	an	moderate	increase	of	p21	(Figure 21, third
lane). Conversely, overexpression	of	pCAG-YFP-ANKHD1	slightly	reduced	p21	ex-
pression	levels	(Figure 21, fourth	lane). These	data	suggest	ANKHD1	is	able	to	mod-
ulate	p21	expression, which, in	turn, may	contribute	to	the	proliferation	effects	de-
scribed	above.
3.5.4 Akt	and	Erk	activation	is	not	inﬂuenced	by	ANKHD1	levels
Tumor	cells	often	exhibit	 aberrant	 signaling	 in	pathways	 involved	 in	growth	and
proliferation	such	as	Akt	and	Erk. Moreover, our	 lab	and	others	have	previously
shown	that	CD95	can	promote	tumor	growth	and	invasion	by	regulating	Akt	and
Erk	pathways	[47]. We	wanted	to	test	if	ANKHD1	modiﬁes	Akt	or	Erk	levels	to	ful-
ﬁll	its	function	in	GICs	and	if	CD95	driven	activation	of	Akt	or	inhibition	of	Erk	is
blocked	or	enhanced	by	ANKHD1. First, we	measured	if	CD95	activation	with	T4
ligand	had	any	effects	on	ANKHD1	expression	 levels. GBM13	or	GBM30	cells
were	either	left	untreated	or	incubated	with	T4	for	24	and	48	hours. As	shown	in
Figure 22, ANKHD1	levels	did	not	change	to	any	greater	extend	after	CD95	acti-
vation	in	any	of	the	two	tested	GIC cultures, independent	of	the	T4	concentration
used. Next, we	 tested	 if	ANKHD1	can	 interfere	with	CD95	promoted	activation
of	Akt	or	inhibition	of	Erk, and	if	ANKHD1	by	itself	had	any	effect	on	Akt	or	Erk
phosphorylation. To	this	end, GBM13	or	GBM30	cells	were	ﬁrst	electroporated
with	non-targeting	siRNA or	siRNA targeted	against	ANKHD1. 72	hours	later, cells
were	either	left	untreated	or	treated	with	T4	ligand	for	15	or	30	minutes, followed	by
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Figure 19: Flow cytometry dot plots and gating strategy of GIC samples tested for EdU incorpo-
ration. A | GBM 13 cells electroporated with non-targeting siRNA and pCAG-YFP were ﬁrst broadly
gated for living cells (left panel), followed by doublet exclusion (middle left panel), and exclusion of
sub-G1 DNA content events (not shown). Finally YFP positive (middle right panel) and EdU positive
(right panel) cells were identiﬁed. YFP and EdU gates were set against negative controls. B | YFP (left
panel) and EdU (right panel) positive populations in GBM13 cells electroporated with siRNA against
ANKHD1 and pCAG-YFP. C | YFP (left panel) and EdU (right panel) positive populations in GBM13
cells electroporated with pCAG-YFP-ANKHD1. D-F | Same as A-C but for GBM 30 cells.
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Figure 20: ANKHD1 overexpression promotes GIC proliferation in
 vitro. A+C | GBM 13 (A) or
GBM 30 (C) cells were electroporated with either pCAG-YFP together with non-targeting siRNA (CO),
pCAG-YFP together with siRNA targeting ANKHD1 (KD), or pCAG-YFP-ANKHD1 (OE). 72h later cells
were treated with 20µM EdU for 60 minutes, followed by ﬁxation and staining for EdU, YFP and DNA
content. EdU incorporation amongst YFP positive cells was measured by ﬂow cytometry as de-
scribed in Fig. 19. Data are presented as mean ± s.d., n=2, one-way ANOVA, **p < 0.01. B+D |
Knockdown and overexpression of ANKHD1 was conﬁrmed by qRT-PCR.
WB: p21 - 21 kDa
WB: GAPDH - 42 kDa
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Figure 21: ANKHD1 regulates p21 expression levels in GBM 13. GBM 13 cells were either left
untreated, or electroporated with pCAG-YFP together with non-targeting siRNA (NT), pCAG-YFP
together with siRNA targeting ANKHD1 (KD), or pCAG-YFP-ANKHD1 (OE). 72h later cells were har-
vested and lysed, followed by Western blotting for GAPDH (loading control, upper lane), and p21
(lower lane). Changes of p21 expression levels in lanes 2 - 4 relative to untreated cells (lane 1) are
shown below each lane.
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cell	lysate	preparation	and	Western	blotting	for	phosphorylated	and	total	Akt	protein
(pAkt	and	tAkt, respectively), as	well	as	phosphorylated	and	total	Erk	protein	(pErk
and	tErk, resp.). Contrary	to	previous	reports, Akt	activation	was	not	observed	in
GBM13	or	GBM30	cells	following	stimulation	with	10 ng/ml	T4	 (Figure 23A and
B,	lanes	1-3)	or	40 ng/ml	T4	(Figure 23C and	D,	lanes	1-3). Moreover, Erk	phospho-
rylation	and	expression	levels	were	seemingly	not	affected	by	T4	ligand	treatment
in	GBM13	or	GBM30	cells. Knockdown	of	ANKHD1	strongly	decreased	its	protein
levels	in	both	GBM13	and	30	cells	(Figure 23A-D,	lanes	3-6), but	did	not	inﬂuence
Akt	and	Erk	phosphorylation	and	expression	(compare	lane	4	to	lanes	1-3	in	each
panel). Furthermore, knockdown	of	ANKHD1	did	not	 inﬂuence	phosphorylation
and	expression	levels	of	Akt	or	Erk	in	CD95	activated	samples	(Figure 23A-D,	lanes
5	and	6). Together, this	data	suggest	that	ANKHD1	does	not	inﬂuence	Akt	and	Erk
phosphorylation	or	expression	in	GICs.
WB: MLL5
WB: GAPDH
WB: Ankhd1
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Figure 22: ANKHD1 expression levels are not inﬂuenced by CD95 activation in GICs. GBM 13 and
30 cells were left untreated (UT), or were treated with 10 ng/ml (left panel) or 40 ng/ml (right panel)
T4 for 24 or 48 hours before preparation of cell lysates and Western blotting. Membranes were then
tested with the indicated antibodies.
Together, the	presented	data	suggest	that	ANKHD1	is	highly	expressed	in	most	of
the	tested	GIC cultures	and	that	high	ANKHD1	levels	might	contribute	to	the	cells’
proliferation	properties. Moreover, this	function	might, at	least	partially, be	depen-
dent	on	inﬂuencing	p21	protein	levels, while	Akt	and	Erk	signaling	pathways	seem
to	be	unaffected	by	ANKHD1.
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Figure 23: Akt and Erk activity is not inﬂuenced by ANKHD1 knockdown. A | GBM 13 (A) or GBM
30 (B) cells were electroporated with pCAG-YFP together with non-targeting siRNA (CO), or pCAG-
YFP together with siRNA targeting ANKHD1 (KD). 72h later cells were treated with 10 ng/ml T4 for
15 or 30 minutes, or left untreated (UT), followed by cell lysis and Western blotting. Membranes were
tested with the indicated antibodies. B | Same as in A, but with 40 ng/ml T4 treatment and including
testing for tErk and pErk as indicated.
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4 Discussion
The	brain	is	a	very	complex	organ	that	evolved	to	carry	out	all	the	higher	cognitive
functions	–	such	as	reasoning, planning, emotions, and	problem	solving	–	which
are	so	central	 to	what	we	are. The	main	structure	 involved	 in	 these	 functions	 is
the	neocortex. It	 is	 part	 of	 the	dorsal	 forebrain	which	underwent	 a	 tremendous
expansion	in	humans. It	 is	a	seemingly	 impossible	 task	 to	 try	 to	comprehend	its
full	inner	workings—from	the	generation	of	billions	of	brain	cells	to	the	hundreds
of	billions	of	connections	that	are	formed	between	them. And	yet, step	by	step	we
make	great	progress	in	understanding	this	extraordinary	organ. We	have	come	a
long	way	since	the	discovery	of	the	neuron	as	such	by	Jan	Evangelista	Purkinje	in
the	1830s	and	the	fundamental	work	on	brain	anatomy	by	Santiago	Ramón	y	Cajal.
However, despite	the	many	thousands	of	researchers	committed	to	study	the	brain,
we	have	yet	to	solve	the	puzzle	of	fully	comprehending	the	brain.
Many	of	 the	known	diseases	of	 the	brain	are	directly	connected	 to	malfunctions
of	neural	progenitor	cells	(NPCs). For	instance, neurodevelopmental	disorders	are
often	caused	by	de-regulated	proliferation	and	differentiation	behavior	of	NPCs	dur-
ing	brain	development, and	the	cells	of	origin	of	many	cancers	in	the	adult	brain	are
thought	to	be	NPCs. Understanding	how	these	cells	are	regulated	in	the	healthy	or-
ganism	is	crucial	for	the	development	of	treatment	strategies	for	the	diseased	brain.
The	work	presented	in	this	thesis	aims	to	add	to	our	understanding	of	how	normal
and	neoplastic	NPCs	are	regulated. We	investigated	the	role	of	ANKHD1	in	NPCs,
hitherto	without	a	described	function	in	these	cells. We	have	shown	that	ANKHD1	is
expressed	in	NPCs	of	the	developing	and	adult	brain. Furthermore, we	demonstrated
by	loss	and	gain	of	function	approaches	that	ANKHD1	is	important	for	regulation	of
embryonic	and	adult	NPCs. Knockdown	of	ANKHD1	caused	increased	proliferation
and	inhibited	differentiation	in	NPCs. ANKHD1	does	not	seem	to	bind	to	SHP2	to
control	proliferation	and	differentiation	in	eNPCs	but	might	interact	with	the	Hippo
pathway	components	instead.
Interestingly, in	cultured	glioma	initiating	cells	(GICs), overexpression	of	ANKHD1
promoted	proliferation, while	knockdown	showed	no	pronounced	effect. Akt	and
Erk	signaling	seemed	to	be	unaffected	by	ANKHD1	knockdown	in	GICs, while	p21
protein	expression	was	slightly	increased.
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Together, our	data	suggest	that	ANKHD1	is	expressed	in	embryonic	and	adult	NPCs
and	is	an	important	regulator	of	their	proliferation	and	differentiation	behavior.
4.1 The	ANKHD1	gene	across	species
ANKHD1	is	a	recently	discovered	and	still	poorly	studied	protein. It	has	ﬁrst	been
described	in	Drosophila	melanogaster	[84]	and	shortly	later	in	mammals, including
humans	[65]. Comparison	of	the	human	ANKHD1	gene	sequence	with	genomes
from	other	organisms8 revealed	that	genes	homolog	to	ANKHD1	can	be	found	in
many	different	species, belonging	to	various	animal	classes. Genes	with	more	than
80%	sequence	identity	to	ANKHD1	include	species	in	the	classes	of Insecta, Aves,
Reptilia, Bivalvia, Anthozoa, and Amphibia. The	gene	duplication	event	 that	 led
to	the	emergence	of	the	ANKHD1	paralog	ANKRD17	occurred	in	vertebrates. The
relation	between	the	two	proteins	is	poorly	studied	and	it	is	unclear	if	they	can	com-
pensate	for	each	other	in	some	organisms	or	tissues. In	mice, knockout	of	ANKRD17
has	severe	effects	[38]	suggesting	that	gene	compensation	of	these	two	proteins	is
unlikely	in	mammals. Furthermore, we	have	compared	sequences	stretches	of	par-
ticular	interest	within	the	ANKHD1	gene	–	such	as	the	putative	nuclear	localization
signal	–	and	found	them	to	be	highly	conserved	among	all	mammals	tested	and	even
across	species	of	other	animal	classes. Hence, ANKHD1	is	an	evolutionary	old	pro-
tein	conserved	across	many	species, suggesting	that	it	might	have	a	pivotal	function
in	most	organisms	of	the	animal	kingdom.
4.2 ANKHD1	expression	in	the	mammalian	brain	and	other	tissues
Expression	of	ANKHD1	has	been	experimentally	proven	in	only	a	few	tissues	so	far.
In	Drosophila, the	ANKHD1	homolog	MASKwas	found	to	be	expressed	ubiquitously
during	development	[84]. Similarly, ANKHD1	seems	to	be	expressed	ubiquitously
in	mammals. Expression	of	ANKHD1	mRNA in	mammalian	tissues	was	ﬁrst	reported
by	Poulin	et al. [65] in	2003. The	authors	described	ANKHD1	mRNA levels	deter-
mined	by	qRT-PCR in	 the	brain, eye, spleen, lung, liver, smooth	muscle, kidney,
testis, prostate, and	uterus	of	mice. They	also	 tested	expression	of	 the	ANKHD1
4EBP3	fusion	protein	(mMASK-BP3)	 in	the	same	tissues. Expression	of	ANKHD1
8using	databases	and	tools	provided	by	Ensembl	[24]	and	UniGene	[93]
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was	highest	in	brain	and	eyes. MASK-BP3	expression	was	barely	detectable	in	the
brain, and	a	bit	lower	than	ANKHD1	in	the	eye, while	it	was	strongly	expressed	in
tissues	where	ANKHD1	levels	were	lower, such	as	in	the	kidney	and	testis. Thus,
expression	of	these	two	transcripts	is	not	mutually	exclusive	but	it	seems	that	one	or
the	other	are	preferably	expressed	in	a	given	tissue. The	dominant	transcript	in	the
mouse	brain	seems	to	be	ANKHD1. The	authors	did	not	discriminate	between	dif-
ferent	brain	structures	in	their	qRT-PCR analyses. We	found	very	robust	expression
levels	of	both	ANKHD1	mRNA and	protein	in	short	term	cultured	aNPCs, as	well	as
ANKHD1	mRNA in	the	hippocampus	of	adult	mice	throughout	life. Together, these
data	suggest	that	ANKHD1	is	robustly	expressed	in	the	adult	mouse	brain. Due	to
the	lack	of	suitable	antibodies	or	reporter	mice, a	more	detailed	study	of	ANKHD1
expression	in	the	brain	is	not	feasible. It	would	be	of	interest	to	reveal	if	ANKHD1
is	expressed	in	all	cells	of	the	brain, and	if	expression	levels	are	similar	between
cells. A role	of	ANKHD1	seems	to	be	in	proliferation	control, and	if	it	is	expressed
in	post	mitotic	cells	as	well	it	would	be	intriguing	to	study	if	in	these	cells	ANKHD1
is	involved	in	maintaining	a	non-proliferative	state	or	has	different	functions.
Poulin	et al. [65] also	studied	ANKHD1	expression	by	Northern	blotting	in	human
tissues, including	heart, brain, placenta, skeletal	muscle, and	pancreas. They	found
no, or	only	very	little	expression	of	ANKHD1	in	the	brain. However, it	is	not	clear
which	part	of	 the	brain	 the	 sample	was	 taken	 from, and	 in	which	condition	 the
specimen	was. Contrary	to	this	ﬁnding, immunohistological	images	from	the	Hu-
man	Protein	Atlas	database	[91]	do	indicate	ANKHD1	expression	in	the	adult	human
brain. Images	of	histological	sections	of	the	cortex	show	a	strong	signal	in	neuronal
cells. Expression	is	also	observable	in	other	brain	areas	and	tissues. There	are	two
limitations	 to	this	dataset: (i)	 these	data	were	not	validated, and	(ii)	 the	antibody
used	can	also	detect	the	MASK-BP3	fusion	protein. Since	Poulin	et al. [65] did	not
detect	MASK-BP3	in	their	human	brain	sample	either, it	is	not	clear	to	which	ex-
tend	ANKHD1	is	expressed	in	the	human	brain. More	detailed	qRT-PCR expression
studies	and	validation	of	the	human-protein-atlas	data	with	the	same	antibody, but
if	possible	also	with	one	that	speciﬁcally	recognizes	ANKHD1	and	not	MASK-BP3,
are	needed	to	clarify	expression	patterns	in	the	human	brain.
Expression	of	ANKHD1	in	the	developing	mammalian	brain	has	not	been	demon-
strated	so	far. As	mentioned	above, MASK is	expressed	ubiquitously	during	Droso-
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phila	development, including	the	brain. Databases	such	as	the	Allen	Brain	Atlas	of
the	developing	mouse	brain	[3]	or	the	EMAP project	[89]	do	not	yet	include	data
on	ANKHD1. We	have	shown	for	the	ﬁrst	time	that	ANKHD1	is	expressed	in	the
developing	mammalian	brain. We	have	used	qRT-PCR, in	situ hybridization, and
Western	blotting	 to	 investigate	ANKHD1	expression	 in	 the	developing	 forebrain.
For	qRT-PCR detection	of	ANKHD1	we	dissected	the	complete	dorsal	telencephalon
(without	skin	and	meninges	layers)	from	various	embryonic	stages, from	which	we
then	isolated	mRNA.	This	means	that	all	cell	types	present	in	the	tissue	at	the	time
were	included	in	the	analysis. For	early	stages	( E12.5)	the	neocortical	tissue	con-
sist	mainly	of	radial	glia	(RG),	and	some	early	born	neurons. Very	few	other	types
of	progenitors	are	present. During	mid-embryonic	stages	the	proportion	of	RG is
reduced	and	many	basal	progenitors	(BPs)	and	neurons	are	present. With	ongoing
development	more	differentiated	glia	cells	are	added. Therefore	we	could	not	dis-
tinguish	the	cell	type(s)	that	express	ANKHD1	in	the	developing	cortex. Because
we	detected	ANKHD1	expression	from	the	early	stages	on	(i.e. E12.5), it	is	likely
that	it	is	expressed	in	eNPCs. We	next	performed in	situ hybridization	experiments
to	analyze	ANKHD1	in	more	detail. We	found	broad	expression	of	ANKHD1	at
E13.5, including	in	the	ventricular	and	subventricular	zones. Together, these	data
strongly	suggest	that	ANKHD1	is	expressed	in	eNPCs. Finally, we	could	show	that
the	ANKHD1	protein	is	indeed	translated	during	neocortical	development	by	West-
ern	blotting. Due	to	lack	of	suitable	antibodies, ANKHD1	expression	could	not	have
been	investigated	in	more	detail	on	mouse	brain	sections. It	would	be	of	interest	to
see	if	ANKHD1	in	the	brain	is	truly	ubiquitous	and	of	similar	intensity	in	different
cell	types.
4.3 The	function	of	ANKHD1	during	mammalian	brain	development
Thus	far, only	studies	performed	in	Drosophila	have	shown	a	function	for	ANKHD1
in	progenitor	cells	during	development, and	no	studies	regarding	brain	development
have	been	conducted. Smith	et al. [84] showed	that	MASK is	essential	for	early	em-
bryogenesis, since	most	MASK loss-of-function	mutants	are	embryonic	lethal, and
that	 it	 is	 later	required	for	normal	proliferation	and	differentiation	of	photorecep-
tor	progenitor	cells. Sansores-Garcia	et al. [74] and	Sidor	et al. [81] observed	a
signiﬁcant	reduction	of	eye	and	wing	size	in	mask	null	or	knockdown	mutants.
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We	have	shown	that	ANKHD1	is	expressed	in	embryonic	and	adult	NPCs	of	mice.
To	elucidate	its	function	in	these	cells	we	performed	several in	vitro and in	vivo loss-
and	gain-of-function	experiments	in	embryonic	and	adult	NPCs.
ANKHD1	knockout	mice	would	be	of	great	value	to	study	the	function	of	ANKHD1
during	development	but	are	unfortunately	not	available	yet. Transient	manipulation
in	dissociated	primary	cultures	of	eNPCs	can	provide	good	insights	 into	possible
functions	but	does	not	resemble	the in	vivo situation	and	hence	might	not	be	sufﬁ-
cient	to	draw	solid	conclusions. In	order	to	study	ANKHD1	function	in	the	develop-
ing	mammalian	brain in	vivo, we	used	the in	utero electroporation	technique. With
this	technique	it	is	possible	to	speciﬁcally	manipulate	RG cells	in	the	developing
brain	[88]	and	to	follow	their	daughter	cells. The	manipulation	via in	utero elec-
troporation	is	spatially	restricted	to	the	injection	site	and	the	region	were	electrodes
are	applied. For	instance, the	dorsal	pallium	can	be	targeted	without	affecting	the
ventral	pallium, and	thus	tangentially	migrating	cells	 invading	the	neocortex	(see
1.3.1)	will	not	inﬂuence	and	be	mixed	up	with	locally	produced, radially	migrating
daughter	cells	of	RG.	 Importantly, not	all	cells	 in	 the	electroporated	area	will	be
transfected	and	thus	the	study	of	cell	extrinsic	effects	might	be	limited. Compared
to	knockout	mice, in	utero electroporation	has	several	advantages	(e.g. it	allows	to
overcome	compensatory	mechanisms	of	gene	redundancy, different	brain	regions
can	be	targeted, combinatorial	knockdown	of	two	or	more	genes	may	be	easily	per-
formed, etc.) but	also	a	few	disadvantages	(e.g. the	special	equipment	required,
and	difﬁculties	for	studying	early	development). Reiner	et al. [67] compared	ob-
servations	in	knockout	mice	and	knockdown	via in	utero electroporation	with	the
doublecortin	superfamily	as	example. The	authors	described	how	using in	utero
electroporation	might	overcome	compensatory	mechanisms	of	gene	redundancy	in
the	doublecortin	superfamily	and	thus	better	information	could	have	been	obtained
from	single	gene	knockdown	experiments	compared	to	single	gene	knockout	mice,
which	did	not	show	obvious	phenotypes	in	this	case. The in	utero electroporation
method	is	often	utilized	in	studies	of	mammalian	brain	development	and	has	proven
to	be	 reliable, despite	of	 some	cases	 in	which	conﬂicting	 results	were	produced
compared	to	knockout	mice	[67].
First, we	wanted	to	investigate	the	effects	of	ANKHD1	knockdown	on	developing
cells	 in	 the	 neocortex. We	 used	 a	 pool	 of	 four	 siRNAs	 directed	 against	mouse
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ANKHD1	to	knock	it	down	in	RG of	E13.5	or	E14.5	embryos. We	then	analyzed
transfected	cells	48	hours	later	with	various	methods. The	48	hour	time	window
between in	utero electroporation	and	analysis	is	long	enough	to	allow	knockdown
of	the	protein	and	generation	of	several	daughter	cells, but	still	short	enough	to	ne-
glect	dilution	and	degradation	effects	of	electoporated	plasmids	or	siRNA.	We	ﬁrst
analyzed	transfected	cells	for	EdU incorporation	by	ﬂow	cytometry	to	measure	cell
proliferation. Interestingly, we	observed	that	proliferation	of	NPCs	was	increased
in	cells	with	knock	down	of	ANKHD1. We	then	analyzed	ANKHD1	knockdown
cells	on	cryosections	with	markers	 for	RG,	BPs, and	neurons. The	proportion	of
both, RG and	BPs	was	 increased, while	 the	number	of	newly	born	neurons	was
decreased	 in	ANKHD1	knockdown	cells. These	data	suggest	 that	knockdown	of
ANKHD1	promotes	proliferation	and	inhibits	differentiation	to	neurons. In	Droso-
phila	photoreceptor	progenitors, loss	of	MASK similarly	leads	to	a	lower	number	of
differentiated	cells. However, the	authors	did	not	observe	more	proliferation, they
rather	suggested	that	apoptosis	is	increased. Sansores-Garcia	et al. [74] and	Sidor
et al. [81] demonstrated	that	loss	of	mask	leads	to	smaller	organs. This	suggests	that
loss	of	ANKHD1	would	rather	promote	differentiation	than	inhibiting	it, generating
insufﬁcient	numbers	of	differentiated	cells. However, it	 is	also	possible	that	cells
without	ANKHD1	initially	 fail	 to	differentiate	and	 thus	are	kept	 in	a	proliferative
state. Some	of	 these	cells	might	differentiate	eventually, other	which	 later	 fail	 to
differentiate	still, might	die	and	thus	lead	to	smaller	organs	in	the	end. We	did	not
measure	apoptosis	here, however, total	cell	numbers	between	knockdown	and	con-
trol	conditions	did	not	seem	to	be	different, suggesting	that	apoptosis	does	not	play
a	big	role, at	least	in	early	stages	after	ANKHD1	knockdown. In	mice, ANKHD1
might	play	an	active	role	in	promoting	proliferation	and	thus	initially	inhibiting	dif-
ferentiation. Control	of	proliferation	and	differentiation	are	tightly	coupled	and	thus
it	is	often	not	possible	to	distinguish	if	a	protein	is	required	only	for	one	of	these	pro-
cesses	or	both. Some	differences	in	Drosophila	MASK and	mouse	ANKHD1	might
of	course	exist	due	to	differences	in	the	two	proteins: While	the	ankyrin	and	KH
domains	are	well	conserved, other	parts	differ	signiﬁcantly. No	functional	domains
have	been	annotated	apart	from	the	ankyrin	and	KH domains, but	they	still	might
be	pivotal	 for	 the	 function	of	 the	protein. Moreover, MASK is	1500	amino	acids
longer	 than	ANKHD1. How	this	additional	residues	contribute	to	the	function	of
the	protein	is	not	known.
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Co-labeling	of	electroplated	cells	with	markers	for	RG,	BPs, and	neurons	revealed
that	both	RG and	BP pools	were	expanded. We	used	expression	of	the	transcrip-
tion	factor	Tbr2	to	distinguish	RG from	BP cells. Tbr2	was	shown	to	be	exclusively
expressed	in	BPs	[23], and	hitherto	remains	the	only	reliable	marker	to	distinguish
BP from	RG,	beside	 some	morphological	 characteristics. Interestingly, the	num-
ber	of	apical	and	basal	progenitors	was	 increased, while	 the	number	of	neurons
was	decreased	after	ANKHD1	knockdown. These	data	suggest	that	ANKHD1	has
a	function	in	RG cells. ANKHD1	could	promote	the	asymmetric	division	of	a	RG
cell	that	leads	to	the	generation	of	a	neuron	and	RG.	After	knockdown	of	ANKHD1,
RG cells	might	self-renew	and	generate	a	BP rather	than	a	neuron. However, the
relative	increase	of	RG cells	might	be	explained	by	a	blocked	differentiation	to	both
neurons	and	BPs, or	a	switch	form	asymmetric	to	symmetric	division	of	RG cells.
The	expansion	of	BP cells	after	knockdown	of	ANKHD1	was	more	prominent	then
the	increase	in	RG cells. As	mentioned	above, this	effect	can	be	explained	in	part
by	RG cells	that	shift	to	producing	a	BP rather	than	a	neuron. A second	possibility	is
that	BPs	undergo	additional	rounds	of	divisions	instead	of	differentiating	to	neurons.
Cell	cycle	exit	is	tightly	coordinated	with	the	initiation	of	differentiation	[64]. We
have	observed	a	strong	decrease	in	the	number	of	produced	neurons	when	ANKHD1
was	knocked	down. A shift	of	asymmetric	RG division	from	neurons	to	BPs	is	most
likely	not	sufﬁcient	to	explain	the	decrease	in	neurons. Especially	because	at	this
time	of	development, the	main	neurogenic	phase, most	RG division	already	produce
BPs, and	RG to	neuron	division	are	less	frequent. A change	in	RG differentiation
mode	without	affecting	differentiation	of	BPs	 into	neurons	would	not	 lead	 to	 the
observed	extend	of	neuron	production	decrease. Moreover, we	measured	a	strong
increase	in	EdU incorporation, again	suggesting	that	BPs	undergo	additional	rounds
of	divisions	instead	of	differentiation. Together, our	data	suggest	that	it	is	less	likely
that	expansion	of	BPs	and	decrease	in	neurons	is	solely	due	to	RG cells	division
behavior	and	rather	a	signiﬁcant	contribution	comes	from	enhanced	BP proliferation
and	inhibited	differentiation	of	BPs	to	neurons.
Apart	from	RG and	BP cells, some	other	progenitor	cell	types	have	been	described
(see	introduction). However, these	cells	are	not	very	abundant, poorly	studied	and
molecular	markers	for	 their	 identiﬁcation	are	lacking. Hence, we	did	not	further
investigate	if, e.g. basal	RG or	SNPs	are	more	affected	by	ANKHD1	knockdown
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than	RGs	or	BPs.
The	number	of	neurons	was	reduced	in	ANKHD1	knockdown	cells	48	hours	post in
utero electroporation. Apart	from	a	complete	blockade	of	differentiation, it	might	be
that	it	is	only	delayed. Indeed, when	we	compared	P2	brains, we	did	not	notice	an
apparent	difference	in	the	number	of	neurons	reaching	the	cortical	plate. However,
knockdown	of	ANKHD1	was	only	transient	and	thus	its	effect	might	be	diluted	and
less	apparent	at	later	stages. More	detailed	analyses	of	post	natal	brains	and	usage
of	long	term	knockdown	/	knockout	strategies	are	necessary	to	unravel	the	complete
effect	of	loss	of	ANKHD1	in	differentiating	neurons. We	did	not	observe	misexpres-
sion	of	markers	in	areas	were	they	are	usually	not	present, i.e. neuronal	markers
in	 the	VZ or	SVZ or	an	expansion	of	the	SVZ (Tbr2	positive	cells). The	additional
BPs	we	observed	after	KD of	ANKHD1	were	all	accumulating	in	their	appropriate
location	(the	SVZ).	This	suggests	that	migration	of	proliferating	and	differentiating
cells	is	not	affected	by	ANKHD1.
Conversly, when	we	overexpressed	human	ANKHD1	in	eNPCs, more	cells	differ-
entiated	into	neurons. As	mentioned	before, human	and	mouse	ANKHD1	are	very
similar	and	probably	can	substitute	each	other. After	we	found	that	human	ANKHD1
is	able	to	promote	differentiation	in	mouse	eNPCs, we	hypothesized	that	overex-
pression	of	ANKHD1	might	 rescue	 the	knockdown	phenotype	we	observed. In-
deed, simultaneous	knockdown	of	mouse	ANKHD1	and	overexpression	of	human
ANKHD1	reverted	proliferation	and	differentiation	rates	close	to	control	levels. A
partial	rescue	is	not	surprising, especially	because	overexpression	of	ANKHD1	is
quite	 inefﬁcient	due	 to	 its	 size. Together, these	data	 suggest	 that	 knockdown	of
ANKHD1	leads	to	an	expansion	in	the	RG and	BP pool	and	thereby	inhibits	differ-
entiation	into	neurons.
4.4 The	role	of	ANKHD1	in	adult	NPCs
We	have	found	that	ANKHD1	is	expressed	in	isolated	adult	NPCs. Expression	pat-
terns	through	the	adult	brain	have	not	been	examined	in	more	detail	due	to	lack	of
suitable	antibodies. We	are	currently	generating	a	reporter	mouse	that	will	allow
detailed	analysis	of	ANKHD1	expression	patterns.
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To	investigate	if	ANKHD1	might	play	a	similar	role	in	aNPCs	as	in	eNPCs	we	per-
formed in	vitro proliferation	and	differentiation	assays. We	used	aNPCs	 isolated
from	the	SVZ of	adult	mice	which	were	then	cultured	in	serum	free	media	as	neu-
roshperes. Cells	isolated	and	cultured	this	way	were	shown	to	retain	aNPC charac-
teristics	(e.g. differentiation	to	neurons, astrocytes, and	oligodendrocytes)	and	can
be	transplanted	into	the	adult	mouse	brain, where	they	engraft, survive	and	produce
differentiated	cells	[29, 68].
Knockdown	of	ANKHD1	in	aNPCs	similarly	led	to	an	increase	in	EdU incorporation
as	in	eNPCs. Moreover, knockdown	of	ANKHD1	in	an	aNPC differentiation	assay
caused	 fewer	neurons	 to	 form. Conversely, overexpression	of	ANKHD1	 resulted
in	more	differentiated	neurons. These	data	suggest	that	ANKHD1	might	have	con-
served	functions	in	aNPCs. However, in	vivo experiments	will	be	needed	to	fully
understand	the	role	of	ANKHD1	in	aNPCs. For	instance, virus	mediated	knockdown
of	ANKHD1	in	aNPCs	of	the	SVZ could	be	utilized	to	verify	proliferation	and	differ-
entiation	phenotypes	observed in	vitro. Furthermore, conditional	knockout	(cKO)
mice	for	ANKHD1	will	allow	detailed	analysis	of	phenotypes	associated	with	loss
of	ANKHD1	in	aNPCs.
Conserved	functions	of	genes	in	embryonic	brain	development	and	adult	NPCs	are
not	surprising	and	have	been	studied	extensively. For	instance, the	Notch	signaling
pathway	was	shown	to	be	crucial	for	”stem	cell”	maintenance, similar	to	the	role	in
RG cells	during	embryonic	development. However, due	to	the	very	different	envi-
ronment	that	aNPCs	face, also	additional	and	/	or	alternative	functions	for	proteins
known	from	development	have	been	described. For	instance, Wnt	signaling	Exam-
ples? at	least	refs. Future	work in	vivo will	shed	more	light	into	the	functions	of
ANKHD1	in	the	adult	brain.
4.5 Involvement	of	ANKHD1	in	GBM
GBM presumably	originates	form	progenitor	cells	in	the	brain. However, exactly
which	kind	of	progenitor	cell	might	be	the	cell	of	origin	is	currently	under	debate.
Apparently	these	progenitors	might	be	oligodendrocyte	progenitor	cells	(OPCs)	rath-
er	than	aNPCs. Of	note, OPCs	develop	from	embryonic	or	adult	NPCs	(see	introduc-
tion). It	is, however, important	to	distinguish	the	cells	that	acquire	and	propagate
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relevant	oncogenic	hits	and	those	cells	that	are	in	the	right	environment	and	state
that	permits	cancers	to	develop	[87]. Independent	of	the	debate	over	which	cells
exactly	have	 the	capabilities	 to	 form	tumors, it	has	become	clear	 in	recent	years
that	NPCs	are	involved	in	this	process. Thus, signaling	pathways	and	components
relevant	in	NPCs	are	often	found	to	be	de-regulated	in	GBM and	display	interesting
targets	for	treatment	strategies.
ANKHD1	was	suggested	to	be	involved	in	cancer	biology	of	solid	and	suspension
tumors	[92, 74]. It	was	shown	that	ANKHD1	is	overexpressed	in	acute	leukemias
[92], can	contribute	to	cell	cycle	progression	in	multiple	myeloma	cells	[19], and
that	low	levels	of	ANKHD1	are	beneﬁcial	for	relapse-free	survival	of	breast	cancer
patients	[74]. We	have	identiﬁed	ANKHD1	as	regulator	of	NPC proliferation	and
thus	wanted	to	investigate	if	it	is	invovled	in	GBM biology	as	well, similar	to	other
cancer	types	described	above.
We	obtained	surgical	specimens	of	GBM resections	which	were	subsequently	cul-
tured	in	serum	free	conditions	to	enrich	for	”cancer	stem	cells”	or	”glioma	initiating
cells”	(GICs). These	cells	were	shown	to	form	tumors	when	injected	orthotopically
into	immune-comprimised	mice, and	–	to	a	certain	extend	–	resemble	the	primary
tumor	phenotype	[82]. These	phenotypic	features	include	the	differentiation	to	var-
ious	cell	types	and	the	invasive	nature	of	GBM.	Moreover, serial	transplantation	of
these	cells	 suggest	 that	 it	 is	 indeed	a	population	capable	of	 tumor	 initiation	and
sustainable	tumor	growth.
We	used	these	GICs	to	gain	ﬁrst	insights	into	the	role	of	ANKHD1	in	GBM.	First,
we	examined	ANKHD1	expression	in	various	GIC samples. Indeed, ANKHD1	was
expressed	in	all	GIC samples	tested. Levels	of	expression	varied	signiﬁcantly	be-
tween	 samples, and	 tended	 to	 increase	with	passages	of	 cultures	 (not	quantiﬁed
observations). All	expression	levels	measured	were	higher	compared	to	a	human
brain	parenchyma	lysate	control. The	precise	origin	 (i.e. what	part	of	 the	brain)
of	the	sample	is	unknown	and	more	control	samples	of	deﬁned	origin	are	need	to
clarify	expression	of	ANKHD1	in	adult	human	brain. Especially	a	sample	of	human
adult	neural	progenitor	cells	would	be	the	ideal	control	sample	to	compare	expres-
sion	levels	too. Nonetheless, elevated	ANKHD1	levels	in	other	cancers	have	been
described. Traina	et al. [92] reported	that	ANKHD1	is	overexpressed	in	leukemias.
The	group	determined	levels	of	acute	lymphoblastic	leukemias	and	acute	myeloid
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leukemias	by	qRT-PCR and	compared	them	to	normal	hematopoeitic	cells. Most	of
the	38	leukemia	samples	had	elevated	mRNA levels, but	it	is	not	clear	if	the	pro-
tein	levels	are	similarly	elevated. The	same	group	later	reported	elevated	ANKHD1
mRNA levels	 in	multiple	myeloma	[19]. Notably, all	of	 the	establishes	 leukemia
cell	 lines	Traina	et al. [92] and	Dhyani	et al. [19] tested	showed	strong	ANKHD1
expression	by	Western	blotting. We	have	also	observed	ANKHD1	to	be	highly	ex-
pressed	in	established	cancer	cell	lines, including	K562	and	HEK 293	cells. It	is	not
clear	if	this	high	levels	on	cancer	cell	lines	are	related	to	the	fact	that	the	cells	are
of	a	cancerous	origin, or	rather	have	to	do	with	culturing	conditions	and	cell	cell
contact	(see	below). Finally, Sansores-Garcia	et al. [74] compared	expression	data
from	breast	cancer	patients	and	found	that	ANKHD1	expression	is	heterogenous	in
these	samples, and	more	importantly	that	low	ANKHD1	levels	correlated	with	better
relapse	free	survival.
Functional	roles	of	ANKHD1	in	tumors	are	poorly	studied. Dhyani	et al. [19] have
shown	that	knockdown	of	ANKHD1	in	multiple	myeloma	cells	inhibited	their	pro-
liferation	and	G1	to	S phase	transition	of	 the	cell	cycle. In	NPCs, we	found	that
knockdown	of	ANKHD1	rather	leads	to	higher	proliferation	rates	and	that	overex-
pression	favors	differentiation	of	cells. Therefore	it	was	of	interest	to	test	the	inﬂuence
of	ANKHD1	on	proliferation	of	GBM cells. Surprisingly, proliferation	was	increased
signiﬁcantly	when	we	overexpressed	ANKHD1	in	GICs. We	did	not	observe	sig-
niﬁcant	 effects	on	proliferation	after	ANKHD1	knockdown	 in	 the	 same	 samples.
While	these	results	are	consistent	with	published	ﬁndings, our	observations	in	em-
bryonic	and	adult	NPCs	suggest	an	opposing	function	for	ANKHD1. Though	this
ﬁnding	is	quite	puzzling, opposing	roles	for	a	molecule	in	normal	and	neoplastic
cells	have	been	reported	before	[101]. Interestingly, we	did	not	measure	less	pro-
liferation	when	ANKHD1	was	knocked	down	in	GICs. Possibly	the	present	culture
conditions	(including	growth	factors	EGF and	bFGF) are	sufﬁcient	to	sustain	growth
with	lower	ANKHD1	levels. The	two	GIC samples	that	we	used	for	knockdown	and
overexpression	experiments	displayed	 robust	expression	of	ANKHD1	and	knock-
down	with	siRNA was	very	efﬁcient	in	both	of	them. Despite	the	high	expression	of
ANKHD1	in	these	two	GIC samples, overexpression	further	increased	mRNA lev-
els	ﬁve	to	ten	fold. Apparently, further	increase	of	ANKHD1	expression	still	could
enhance	proliferation.
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Together, our	ﬁndings	support	 that	ANKHD1	might	be	highly	expressed	 in	many
GBM cells	and	promote	their	proliferation, similar	to	its	function	in	leukemia	cells.
Further	work, especially in	vivo, will	be	needed	to	elucidate	the	function	of	ANKHD1
in	GBM.
4.6 Controversy	in	functions	of	ANKHD1	in	NPCs	and	GICs
As	mentioned	above, we	observed	opposing	effects	of	ANKHD1	in	NPCs	and	GICs.
While	in	NPCs	ANKHD1	seems	to	inhibit	proliferation	and	promote	differentiation,
we	actually	observed	stronger	proliferation	of	GICs	in	which	ANKHD1	was	overex-
pressed. How	this	varying	outcomes	are	established	is	not	clear. However, similar
cases	have	been	reported	for	other	proteins	before, or	are	evident	from	studying	the
literature	[49, 79, 101].
For	instance, blockage	of	the	transmembrane	receptor	integrin6	was	shown	to	have
different	outcomes	in	aNPCs	and	GICs. Disruption	of	integrin6	function in	vivo
caused	SVZ aNPCs	to	move	away	from	blood	vessels	and	stimulated	their	prolifer-
ation	[79]. On	the	other	hand, blocking	the	laminin–integrin6	interaction	in	GICs
reduced	proliferation	and	tumorsphere	formation	capacity, and	increased	cell	death
[49]. These	different	outcomes	could	be	due	to	altered	requirements	for	niche	in-
teractions	of	aNPCs	and	GICs. The	precise	mechanism	underlying	 this	behavior
remains	elusive.
Another	examples	for	such	paradox	behavior	is	found	in	the	E2F transcription	fac-
tors. E2F–1	to	5	can	regulate	human	telomerase	reverse	transcriptase	(TERT) gene
expression	by	binding	to	its	promoter. TERT is	the	catalytic	subunit	of	telomerase,
which	is	active	in	cells	with	high	proliferative	potential, such	as	stem	cells. Won
et al. [101] have	shown	that	all	ﬁve	isoforms	of	E2F activate	hTERT transcription	in
normal	human	somatic	cells. In	tumor	cells, however, E2F–1	to	3	(but	not	4	and	5)
repressed	TERT expression. Here	again, the	precise	molecular	mechanisms	causing
this	opposing	behavior	are	not	known.
Thus, it	is	plausible	to	assume	that	ANKHD1	indeed	exhibits	opposing	roles	in	NPCs
and	GICs, similar	to	the	above	mentioned	examples. It	is	currently	unknown	if	pro-
tein	binding	via	 the	ankyrin	 repeats	or	RNA binding	via	 the	KH domain	are	dif-
ferentially	 required	 for	ANKHD1’s	opposing	 functions. It	will	be	of	high	 interest
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to	elucidate	the	precise	pathways	and	molecules	involved	in	ANKHD1	function	in
both	NPCs	and	GICs.
4.7 Signaling	mechanism	of	ANKHD1
Published	data	as	well	as	our	own	work	suggests	that	ANKHD1	functions	in	prolifer-
ation	control	of	cells. How	this	function	is	executed	in	the	cell	is	largely	unknown.
Work	in	Drosophila	[84]	and	leukemia	cells	[92]	revealed	that	ANKHD1	can	inter-
act	with	the	protein	tyrosine	phosphatase	SHP2	genetically	and	physically, respec-
tively. SHP2	is	known	to	be	crucial	for	proliferation	and	differentiation	of	embryonic
NPCs. Not	only	does	it	inﬂuence	NPC proliferation	through	Akt	and	Bmi	pathways,
it	is	also	important	for	the	timed	switch	from	neurogenesis	to	gliogenesis	through
Erk	and	Jak/Stat	pathways. Thus, it	was	very	intriguing	to	hypothesize	that	ANKHD1
might	interact	with	SHP2	in	murine	NPCs	to	control	proliferation	and	differentiation.
To	test	this	hypothesis, we	tried	to	co-immunoprecipitate	SHP2	with	ANKHD1	from
lysates	of	E13.5	NPCs. Both	proteins	were	readily	detectable	in	the	lysate	and	could
be	immunoprecipitated	with	their	respective	antibodies. Unfortunately, we	could
not	co-immunoprecipitate	(co-IP) the	two	proteins	in	NPC lysates. Either	the	co-IP
in	NPCs	is	technically	not	feasible	with	endogenous	proteins, or	they	simply	do	not
interact	in	these	cells. Notably, we	also	failed	to	repeat	the	co-IP published	in	K562
cells. Co-IP with	one	of	the	proteins	overexpressed	and	tagged	might	provide	further
insight, but	will	not	prove	the	interaction	of	endogenous	proteins.
Recently, Sansores-Garcia	et al. [74] and	Sidor	et al. [81] have	shown	that	ANKHD1
can	interact	with	the	Hippo	pathway	effector	protein	YAP in	Drosophila	and	HEK293
cells. The	Hippo	pathway	is	important	for	cell	growth	and	proliferation, and	is	often
deregulated	in	cancer. Less	is	known	about	its	role	in	NPCs, though	some	publi-
cations	reported	expression	of	 the	downstream	effectors	YAP/TAZ in	chicken	and
murine	NPCs	and	their	function	in	proliferation	control	during	neural	development
[11, 50]. We	started	to	investigate	if	ANKHD1	interacts	with	Hippo	pathway	com-
ponents	during	neocortical	development. We	could	not	ﬁnd	an	interaction	between
YAP and	ANKHD1	in	eNPCs. Currently, the	interaction	with	TAZ is	being	probed.
Sidor	et al. [81] suggested	that	ANKHD1	might	translocate	to	the	nucleus	together
with	YAP.	Before	this	study	was	published, we	have	independently	found	a	possible
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nuclear	localization	signal	(NLS) located	behind	the	second	ankyrin	repeat	domain.
Sidor	et al. [81] seem	to	locate	the	NLS at	a	similar	position, though	they	do	not
further	comment	on	the	exact	sequence	or	validation	of	it. The	predominant	local-
ization	of	ANKHD1	in	mouse	NPCs	seems	to	be	in	the	cytosol, although	we	could
observe	small	amounts	of	it	in	the	nucleus	by	sub-cellular	fractionation	and	subse-
quent	Western	blotting, as	well	as	imaging	of	overexpressed	YFP-ANKHD1	in	eNPCs
in	vivo. Even	if	only	small	amounts	of	ANKHD1	should	shuttle	to	the	nucleus, they
still	might	be	 functional	 relevant. Indeed, Sidor	et al. [81] were	able	 to	 identify
ANKHD1	in	a	DNA pulldown	experiment	with	a	sequence	of	the	YAP target	gene
diap1. However, Sansores-Garcia	et al. [74], who	all	investigated	the	ANKHD1	-
YAP interaction, did	not	observe	a	YAP dependent	recruitment	of	ANKHD1	to	the
nucleus	or	 its	presence	in	complexes	binding	 to	DNA.	Thus	 the	signiﬁcance	and
function	of	ANKHD1	in	the	nucleus	remains	elusive	and	has	to	further	investigated
in	the	future.
Dhyani	et al. [19] suggested	that	ANKHD1	might	control	cell	cycle	progression	by
regulating	expression	levels	of	the	cyclin	dependent	kinase	inhibitor	p21. It	inhibits
the	activity	of	cyclin	dependent	kinase	(CDK) 1, -CDK2, and	CDK4/6	complexes
thus	 regulating	 cell	 cycle	progression	at	G1	and	S phase. P21	mediates	 growth
arrest	and	cell	senescence. We	observed	that	knockdown	of	ANKHD1	increased
levels	of	p21	protein	 in	GIC cultures, while	overexpression	slightly	decreased	 its
levels. This	effect	is	similar	to	that	reported	in	multiple	myeloma	cells	by	Dhyani
et al. [19]. However, the	measured	change	is	also	quite	small	and	it	is	unclear	if	it
is	sufﬁcient	to	be	solely	responsible	for	the	observed	effects	on	cell	proliferation.
Important	signaling	components	of	survival	and	proliferation	in	GBM include	Akt
and	Erk. It	was	shown	previously	that	external	signals, e.g. via	the	CD95	receptor,
can	stimulate	GBM proliferation	by	increasing	phospho-Akt	and	/	or	phospho-Erk
levels	[47]. We	tested	if	knockdown	of	ANKHD1	inﬂuenced	Akt	or	Erk	levels	or
phosphorylation	in	addition	to	modulating	p21	levels	in	GICs. However, we	failed
to	observe	changes	in	Akt	or	Erk	total	or	phosphorylation	levels	following	knock-
down	of	ANKHD1, independent	of	previous	activation	of	the	CD95	pathway. As
mentioned	above, knockdown	of	ANKHD1	in	these	cells	did	not	have	a	signiﬁcant
inﬂuence	on	proliferation, which	might	 at	 least	 in	part	 explain	why	Akt	 and	Erk
pathways	are	unaffected.
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Interacting	proteins	probably	bind	to	ANKHD1	via	its	ankyrin	repeats. Additionally,
ANKHD1	also	contains	a	type I KH domain	that	can	bind	single	stranded	DNA or
RNA (see 1.5). Indeed, experimental	evidence	suggests	that	ANKHD1	is	a	RNA bind-
ing	protein: Castello	et al. [12] reported	ANKHD1	as	a	mRNA binding	protein	iden-
tiﬁed	in	a	mRNA interactome	screen	([13]). Hitherto, it	is	unknown	which	mRNAs
and	possible	other	RNA species	are	bound	by	ANKHD1, or	if	its	function	in	NPCs	is
based	on	its	RNA binding	ability. We	have	cloned	a	mutated	form	of	ANKHD1	that
lacks	the	KH domain	(ANKHD1-KH).	Unlike in	utero overexpression	of	full	length
ANKHD1, ANKHD1-KH seemingly	failed	to	promote	differentiation	of	developing
neocortical	neurons. More	detailed	work	is	needed	to	elucidate	the	function	of	the
KH domain	in	ANKHD1	during	NPC proliferation	and	differentiation. It	will	be	cru-
cial	to	identify	the	RNAs	bound	to	ANKHD1	via	cross-linking	immunoprecipitation
(CLIP) and	subsequent	sequencing	of	bound	RNA (CLIP-Seq). These	experiments
are	extremely	challenging	and	will	ﬁrst	have	to	be	performed	with	cell	lines	were
plenty	of	cell	material	can	be	generated	for	use	in	CLIP experiments.
Signaling	cascades	and	transcription	factors	are	well	studied	in	neural	development,
but	only	few	roles	for	RNAs	in	this	process	have	been	described	so	far. For	instance,
overexpression	of	microRNA-92b	causes	a	reduction	in	Tbr2	positive	BPs	and	prolif-
eration	[63], and	microRNA-7a	regulates	Pax6	to	control	spatial	origin	of	forebrain
dopaminergic	neurons	[17]. If	ANKHD1	is	involved	in	microRNA biology	or	only
functions	by	interacting	with	mRNA remains	elusive.
4.8 Conclusive	remarks
ANKHD1	is	a	poorly	studied	protein	 in	mammals	and	other	organisms. The	sci-
entiﬁc	evidence	 so	 far, including	our	work, points	 to	 important	 functions	during
organ	development	as	well	as	tumor	biology. However, much	work	is	needed	to
understand	the	role	of	ANKHD1	in	various	tissues	and	cancers.
ANKHD1	seems	to	be	expressed	in	most, if	not	all	tissues	and	most	cell	types	within
tissues. These	cell	types	include	proliferating	as	well	as	post	mitotic	cells. Func-
tions	for	ANKHD1	have	been	described	only	in	proliferating	cells	so	far. While	it
becomes	more	and	more	evident	that	ANKHD1	is	important	for	proliferation	and
differentiation	control, the	precise	 functions	 remain	 largely	elusive	and	might	be
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cell	 type	speciﬁc	and	context	dependent. For	 instance, knockdown	of	ANKHD1
can	have	different	effects	on	normal	and	neoplastic	cells.
The	expression	of	ANKHD1	in	differentiated, post	mitotic	cells	raises	the	question
about	its	function	in	these	cells. One	explanation	is	that	ANKHD1	is	required	for
cell	 cycle	exit	 and	maintenance	of	 a	non-proliferative	 state. Our	own	data	pre-
sented	in	this	thesis	suggest	that	ANKHD1	might	be	upregulated	during	the	course
of	differentiation	from	progenitors	to	neurons, and	thus	promote	neurogenesis. Ele-
vated	levels	of	ANKHD1	in	newly	differentiated	neurons	might	then	help	to	establish
their	neuronal	identity. Such	a	function, however, contradicts	observations	in	can-
cer	cells	(including	our	own	ﬁndings	in	GICs), where	high	ANKHD1	levels	seem
to	be	beneﬁcial	for	tumor	proliferation. It	is	of	course	not	unlikely	that	ANKHD1
exerts	completely	different	functions	in	post-mitotic	cells. Indeed, other	molecules,
including	the	well	studied	Notch	receptor, are	expressed	in	both	proliferating	and
differentiated	cells	and	have	different	function	in	these	two	cell	types. For	instance,
additional	 to	 its	well	described	 function	 in	progenitor	cells, Notch	 is	also	essen-
tialIs	for	synaptic	plasticity	in	some	hippocampal	neurons	[1]. No	such	diverging
functions	 for	ANKHD1	 in	post-mitotic	 cells	 have	been	published	yet. However,
a	collaborating	group	has	observed	that	overexpression	of	ANKHD1	in	neurons	in
Drosophila	brains	causes	a	pronounced	axonal	outgrowth	phenotype.9 This	suggests
that	ANKHD1	might	be	involved	in	axonal	growth	in	development	and	/	or	regen-
eration	and	would	represent	a	cell	proliferation	independent	function	for	ANKHD1
in	post-mitotic	cells.
Another	intriguing	function, though	mostly	speculative	at	this	point, involves	a	role
of	ANKHD1	in	cell	density	sensing. This	hypothesis	stems	from	comparing	expres-
sion	patterns	in	suspension	cells, tissues, and	cell	cultures	(of	suspension	or	mono-
layer	grown	cells). A search	in	the	Human	Protein	Atlas	database	[91], revealed	that
45	out	of	the	47	testes	cell	lines	were	classiﬁed	as	having	a	strong	ANKHD1	expres-
sion, with	the	other	two	displaying	a	moderate10 expression	level. Moreover, the
database	contains	expression	data	on	various	leukemia	samples	as	well	as	periph-
eral	blood	monocyte	cells, all	of	which	are	classiﬁed	as	stong	ANKHD1-expressing.
Experimental	evidence	for	high	ANKHD1	in	these	cell	types	is	also	present	[19, 92].
9unpublished	data, personal	communication	Bassem	A.	Hassan
10Four	staining	intensities	are	classiﬁed: negative, weak, moderate, and	strong
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In	contrast, expression	in	solid	tissues	seems	to	be	much	more	heterogenous. How-
ever, because	most	of	these	data	come	from	automated	procedures	and	no	experi-
mental	work	was	done	in	most	cases, these	data	need	to	be	interpreted	with	caution
and	validation	will	be	necessary	to	draw	solid	conclusions. Still, it	is	intriguing	to
speculate	that	ANKHD1	expression	might	be	differentially	regulated	in	suspension
cells	and	solid	 tissues, and	 that	 it	 thus	might	have	a	 function	 in	a	 signaling	cas-
cade	related	to	cell	density	detection	/	mechanical	sensing	of	the	cell	environment.
ANKHD1	might	thus	be	involved	in	sensing	organs	size	/	tissue	growth, similar	to
the	function	of	the	Hippo	pathway.
In	 this	 study, we	 have	 provided	 evidence	 for	 expression	 of	ANKHD1	 in	 the	 de-
veloping	mammalian	brain	as	well	as	in	adult	NPCs. We	showed	that	a	primary
function	of	ANKHD1	in	NPCs	is	proliferation	and	differentiation	control, consistent
with	functions	described	in	other	cell	types. Moreover, de-regulation	of	ANKHD1	in
neoplastic	cells	leads	to	increased	proliferation. The	signaling	mechanisms	are	still
largely	unknown, but	might	involve	Hippo	pathway	components, interaction	with
SHP2, and	regulation	of	p21	expression	levels. Future	work	with	reporter	and	(con-
ditional)	knockout	mice	will	help	to	elucidate	the	role	and	signaling	mechanisms	of
this	still	very	mysterious, yet	seemingly	very	important	protein.
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